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ABSTRACT 
Background:  Corticosteroids decrease mortality in COVID-19 patients on intensive respiratory support 
(IRS) but are of uncertain benefit if less severely ill. In a large, national US cohort, we examined 
associations between early corticosteroids and 90-day mortality in hospitalized COVID-19 patients not 
on IRS within 48 hours of admission. 
Methods: We conducted an observational study of patients admitted to a Veterans Affairs Medical 
Center between June 7, 2020-December 5, 2020 within 14-days after SARS-CoV-2 positive test, 
excluding those receiving prior systemic corticosteroids. Amongst patients on only low-flow nasal 
cannula (NC) or no oxygen support (i.e., not on IRS) during initial 48 hours of admission, we compared 
90-day all-cause mortality between those receiving and not receiving oral/parenteral corticosteroids 
within 48 hours with inverse probability weighted Cox proportional hazards models.  
Findings: Of 9,058 total patients (95% men, median age 71 years, 27% black), 6,825 (75%) were not on 
IRS within 48 hours. Among 3,025 patients without oxygen, 598 (20%) received corticosteroids and 283 
(9%) died; of 3,800 patients on NC, 2,808 (74%) received corticosteroids and 514 (13%) died. In stratified 
models comparing those who did and did not receive corticosteroids, patients not on oxygen 
experienced an 89% increased risk for 90-day mortality (hazard ratio [HR] 1.89, 95% confidence interval 
[CI] 1.33-2.68); there was weak evidence of increased mortality among patients on NC (HR 1.21, 95% CI 
0.94-1.57).   
Interpretation: In hospitalized COVID-19 patients on only NC or no oxygen support in first 48 hours, 
corticosteroids showed no mortality benefit at 90-days.  
 




Research in Context  
Evidence before this study  We searched PubMed for all studies published between January 1, 2020- 
June 1, 2021 using search terms COVID-19, corticosteroids and mortality, limiting articles to clinical trials 
and meta-analyses. The most robust prior evidence is from the RECOVERY trial, the largest randomized 
clinical trial demonstrating 28-day mortality benefit of dexamethasone in hospitalized patients with 
COVID-19 related respiratory failure, particularly in patients requiring intensive respiratory support; 
dexamethasone was not associated with mortality benefit in patients not on oxygen. However, the 90-
day mortality benefit of corticosteroids in patients with COVID-19 who require less intensive respiratory 
support remains uncertain.   
Added value of this study  We found that early corticosteroid use within initial 48 hours for hospitalized 
COVID-19 patients is common among patients, including those not on intensive respiratory support 
within the initial 48 hours after admission. We found that corticosteroids were associated with 
increased 90-day mortality in patients on no oxygen and were not associated with mortality benefit in 
patients on nasal cannula within 48 hours of admission.   
Implications of all the available evidence  This study demonstrates that corticosteroids are used 
frequently in hospitalized COVID-19 patients who are on less intensive respiratory support. The lack of 
mortality benefit in patients on low-flow nasal cannula and increased risk of mortality in patients on no 
oxygen suggest that the harms of corticosteroids may outweigh benefits in this population.   
  
INTRODUCTION 
Corticosteroids have emerged as an effective therapy for critically ill patients with COVID-19. The United 
Kingdom RECOVERY trial demonstrated an overall 2.8% absolute decrease in mortality for patients 
treated with dexamethasone compared to usual care.1 When stratified by degree of respiratory support 
at randomization, the magnitude of benefit associated with dexamethasone was greater amongst those 
on invasive mechanical ventilation (IMV) versus supplemental oxygen (inclusive of non-invasive 
mechanical ventilation [NIV]); dexamethasone was not associated with significant mortality benefit 
amongst those not on oxygen. 
 
Dissemination of these and other results led to nearly universal use of corticosteroids for COVID-19 
patients receiving respiratory support, particularly more intensive respiratory support (IRS) such as high-
flow nasal cannula (HFNC), NIV and IMV.2-5 Corticosteroids are also commonly used in patients not on 
IRS, despite being potentially less beneficial. Some studies investigating the association between 
corticosteroids and outcomes among a wider group of patients with COVID-19 – including a larger 
proportion not on IRS than in the RECOVERY trial – have found mixed results.6-10 Variability may be due 
to host factors including immune response to infection, heterogeneity in severity of illness and level of 
respiratory support, duration of infection, and use of different formulations of corticosteroids8 as well as 
residual confounding in observational studies. However, the findings may also suggest that certain 
subgroups of patients with COVID-19 benefit less from corticosteroids.  
 
We sought to determine the association between corticosteroids and mortality using real-world clinical 
data from the Department of Veterans Affairs (VA), the largest integrated healthcare system in the 
United States. In a large, racially and geographically diverse, national cohort of hospitalized COVID-19 
patients, we first assessed patterns of corticosteroid receipt. As nearly all patients on IRS received 
corticosteroids, we limited analysis of associations with 90-day mortality to those not on IRS. Because 
sicker patients are more likely to receive corticosteroids and more likely to die, we used propensity 
score weighting to account for confounding by indication. 
 
METHODS 
Study Design and Population: We conducted an observational cohort study using VA electronic health 
record (EHR) data. We identified an initial cohort of 12,455 patients with COVID-19 admitted to a VA 
hospital within 14 days after a positive polymerase chain reaction (PCR) or antigen test for SARS-CoV-2 
between June 7, 2020 and December 5, 2020.11,12 Prior to June there was little use of corticosteroids in 
the first 48 hours. Index date was defined as date of presentation, including emergency room and any 
time spent under observation status prior to hospital admission if patients were not admitted directly. 
We determined hospital length of stay by concatenating consecutive episodes of care separated by less 
than 24 hours, with first episode of care on the index date identified as day one. Due to changes in 
COVID-19 incidence and treatment protocols over time, we divided the observation period into four 
phases: June 7-July 11; July 12-August 15; August 16-October 17; and October 18-December 5, 2020. 
 
Exclusions: From the initial 12,455 patients, we excluded 3,397. The most common reason was length of 
stay less than 48-hours (n=1,619; 40 deaths), as these patients had insufficient time to receive 
corticosteroids (Figure 1), followed by systemic corticosteroid exposure prior to index date. This was 
defined as any duration of corticosteroids within 14 days, or receipt of corticosteroids for ≥14 days 
within preceding 45 days (n=879). Within each phase, we restricted to facilities with at least 10 cases of 
COVID-19 and at least one corticosteroid prescription (N = 107 facilities) to have sufficient variation and 
number of events at each site. We excluded patients who were transferred from another acute care 
hospital (VA or non-VA) and who were likely incidentally-detected through screening prior to or at 
admission; this included patients who were not admitted to an acute medical care service or had no 
International Classification of Diseases, 10th Revision (ICD-10) codes for COVID-19. We also excluded 101 
patients prescribed hydroxychloroquine yielding a cohort of 9,058 patients.  
 
Respiratory Support: Next, we stratified patients by highest level of respiratory support during the initial 
48 hours of hospitalization: 1) no oxygen support; 2) supplemental low-flow oxygen via nasal cannula 
(NC) that was not identified as a high-flow delivery device; 3) other supplemental oxygen/non-invasive 
ventilation (NIV), inclusive of oxygen by face mask, non-rebreather mask, NIV, or other forms of oxygen 
delivery not identifiable as low-flow NC or high-flow; 4) high-flow oxygen (abbreviated as high flow nasal 
cannula [HFNC]); and 5) invasive mechanical ventilation (IMV). When no evidence of oxygen 
supplementation was found, patients were classified as without oxygen (category 1). IMV was identified 
by structured data sources (ICD-10 procedure and Current Procedural Terminology [CPT] codes). 
Categories 2-4 were assessed from unstructured text notes using natural language processing (NLP) to 
identify key terms indicative of respiratory support. Schemas were developed iteratively with clinician 
review, including appropriate negation terms, based on snippets and note context. Patients on positive 
airway pressure (PAP) for sleep apnea without supplemental oxygen were classified as no oxygen. The 
NLP system was validated on 100 complete patient admissions, comprising 1,093 days reviewed. Fifty 
admissions were double annotated and adjudicated demonstrating Cohen’s kappa of 0.89. At the 
admission-level, receipt of any supplemental oxygen in categories 2-4 (NC, other/NIV and HFNC) was 
identified by the NLP system with a sensitivity, specificity, and positive predictive value of 100%, 77% 
and 94% respectively. When limited to the first 48 hours of admission, the system distinguished patients 
not on oxygen or on NC only from all other categories with 92% accuracy. 
 
Corticosteroid exposure: Corticosteroid administration (inclusive of dexamethasone, prednisone, 
prednisolone, methylprednisolone and/or hydrocortisone) was determined from bar code medication 
administration (BCMA) data (including intravenous). Patients who received at least one dose of an oral 
or parenteral corticosteroid within 48 hours after index date were considered exposed. We also 
determined the number of days during hospitalization that corticosteroids were administered. In each 
phase, we defined corticosteroid administration by site as low (<25th percentile), medium (between 25-
75% percentile), or high (>75th percentile) based on the proportion in the sample receiving 
corticosteroids.  
 
Outcomes: The primary outcome was 90-day all-cause mortality, ascertained using inpatient records and 
VA death registry data to capture deaths outside of hospitalization. All hospitalizations occurred at least 
90 days prior to the most recent mortality data. We also determined the proportion who initiated IMV 
or were administered vasopressors after the first 48 hours. Given low numbers of events, we did not 
conduct multivariable analyses for these outcomes.  
 
Covariates: We used EHR data to obtain demographics (age, race, ethnicity, sex), comorbidities, 
additional medications, and lab results, as well as to calculate the Charlson Comorbidity Index (CCI)13 
and the Veterans Health Administration COVID-19 (VACO) Index.14 We focused on routinely collected 
laboratory tests that have been associated with increased mortality in COVID-1915 including albumin, 
liver function, lactate, white blood cell count, and creatinine (Table 2 and Supplemental Table 1). We 
selected the worst laboratory and vital signs values within the initial 48 hours. To account for potential 
effects of co-prescribed medications on COVID-19 outcomes, we also included use of remdesivir and 
prophylactic anticoagulants within the initial 48 hours.12 Intensive care unit (ICU) admission was 
determined using VA bedsection codes.12,16  
 
Statistical analysis: We initially compared COVID-19 patients by the five respiratory support categories 
using summary statistics (Table 1). Because nearly all patients on IMV or HFNC received corticosteroids; 
there was insufficient variability to allow generation of propensity score weights as discussed below. 
Category 3, “Other/NIV” respiratory support, was heterogenous with respect to support used and illness 
severity. For these reasons, as well as the greater clinical equipoise, we restricted our analysis to 
patients not on IRS (i.e., those on only NC or no oxygen support); from these, we further excluded 28 
patients administered vasopressors in the first 48 hours from subsequent mortality analyses as they 
could have had an alternative indication for corticosteroids. 
 
In those not on IRS, we compared mortality by exposure to corticosteroids stratified by NC and overall. 
To account for confounding by indication, we generated propensity scores for the probability of 
receiving corticosteroids in the first 48 hours using logistic regression. Models included covariates 
thought to be associated with corticosteroid exposure and mortality: comorbidities, laboratory results, 
vital signs, site utilization patterns, co-medications and the 4 phases (Table 2 and Supplemental Table 1). 
We constructed inverse probability of treatment weights (IPTW) from propensity scores for each patient 
to create pseudo-populations with balanced distributions of covariates.17 There was generally very little 
missing data (<5%) so an explicit level for missingness was used for selected covariates. In our primary 
analysis, we used the average treatment effect (ATE) weights, reflecting the overall population from 
which the sample was taken. Stabilized weights were used and the ten patients with the most extreme 
high and low weights were trimmed from the analysis.18 We calculated standardized mean differences 
(SMD) between treatment groups and considered 0.2 or less as balanced. To compare differences in 
survival we generated IPTW Kaplan-Meier (KM) plots19 and Cox proportional hazards models estimating 
the ATE with days since index date as the time scale to provide formal hazard ratio (HR) risk estimates 
with confidence limits using a robust variance estimator. We included the VACO Index in outcome 
models to further account for residual confounding.14  
 
Subgroup and sensitivity analyses: In primary analyses, we included all corticosteroid formulations; in 
subgroup analyses, we restricted to only dexamethasone. We also excluded patients admitted to the 
ICU within the first 48 hours, and restricted to patients age 70 and older. In sensitivity analyses, we 
evaluated the average treatment effect among the treated (ATT) population that received 
corticosteroids in weighted Cox proportional hazards models, and constructed unweighted, but 
multivariable adjusted models for all primary and subgroup analyses (Supplemental Tables 2 and 3).  
 
Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina, USA) and R 
version 4.0.4. Statistical significance was defined as p < 0.05.	Our study was approved by the 
Institutional Review Boards of VA Puget Sound Health Care System, VA Connecticut Healthcare System 
and Yale University, all of whom granted waivers of consent. Study findings are reported as per the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines 
(Supplemental Table 4). 
 
RESULTS 
Patient characteristics, corticosteroid exposure and respiratory support 
Patients hospitalized during the four phases (1,328; 1,564; 1,857; 4,121) were mostly male (95%). 
Median age was 71 years (interquartile range [IQR] 62-77); 55% were non-Hispanic white, 27% non-
Hispanic black, and 9% Hispanic (Table 1). Most patients (81%) were admitted within one day after 
positive SARS-CoV-2 test. More than half (56%) received corticosteroids (95% dexamethasone) within 
the first 48 hours of admission, increasing from 38% in phase 1 to 64% in phase 4. Concurrent remdesivir 
and prophylactic anticoagulants were more common in those who received corticosteroids (remdesivir 
39% vs. 13%; anticoagulants 33% vs. 21%) than in those who did not. 
 
When stratified by highest level of respiratory support provided in the first 48 hours of admission, most 
(77%) patients were on either no oxygen (34%) or NC only (43%) (Table 1). Corticosteroids were 
administered to 20% without oxygen, 74% of patients on NC, 58% on other supplemental oxygen/NIV, 
91% on HFNC, and 92% on IMV. Use of corticosteroids increased over time, particularly in patients on 
NC (Figure 2). Overall, unadjusted 90-day mortality was 17%, and varied by level of respiratory support 
ranging from 9% in those without oxygen, 13% in patients on NC, and 56% in patients receiving IMV 
(Figure 2).  
 
Corticosteroids and mortality in patients not on IRS 
Amongst patients not on IRS, the median duration of inpatient corticosteroids was 5 days (IQR 3-7) in 
patients without oxygen, and 6 days (IQR 4-9) in patients on NC. These were similar to hospital length of 
stay (Table 1). Only 80 (2.6%) and 79 (2.1%) patients, respectively, received one day of inpatient 
corticosteroids.  
 
After propensity score weighting, our samples (pseudopopulations) were well-balanced, with covariates 
showing SMD generally <0.1; both overall and when split by no oxygen vs NC (Table 2 and Supplemental 
Table 1). Among patients without oxygen, weighted KM curves (Figure 3) show that those who received 
corticosteroids had higher mortality over 90-days than those who did not, with differences beginning to 
appear at 20-days after index date. In ATE estimates (Table 3), patients without oxygen who received 
corticosteroids had an 89% increased hazard of 90-day mortality (HR 1.89, 95% CI 1.33-2.68). Results 
were consistent in sensitivity analyses using ATT estimates as well as unweighted, multivariable adjusted 
Cox regression models (Supplemental Table 2).  
 
Similarly, patients on NC who received corticosteroids had higher 90-day mortality than those who did 
not, with weighted KM curves again diverging at 20-days (Figure 3). ATE estimates showed 21% 
increased mortality risk (HR 1.21, 05% CI 0.94-1.57) in patients who were on NC and received 
corticosteroids. HRs were similar in ATT estimates and multivariable Cox models (Supplemental Table 3). 
When combining patients on no oxygen or NC, corticosteroids were associated with an approximately 
60% or more increased mortality risk.  
 
Subgroup analyses 
Results were similar in subgroup analyses restricting corticosteroids to dexamethasone and excluding 
patients who were admitted to the ICU within the first 48 hours (Table 3). Limiting the sample to 
patients age 70 and older, mortality estimates associated with corticosteroids were slightly higher in the 
older population in those on NC. All findings were again consistent using ATT or multivariable Cox 
models (Supplemental Tables 2 and 3).  
 
DISCUSSION 
In this analysis of a national cohort of hospitalized patients with COVID-19, receipt of corticosteroids was 
nearly universal among those on IRS and increasingly common among those not requiring it. Because 
corticosteroid receipt was nearly universal among those on IRS, we could not determine whether there 
was evidence of benefit. However, among patients not on oxygen in the first 48 hours of admission, 
corticosteroids initiated in this window were associated with increased 90-day mortality. Among those 
only on NC in the first 48 hours, corticosteroids were not associated with mortality benefit. Overall, 
when considering those not on IRS together, patients who received corticosteroids had on average a 
60% or greater increase in mortality compared to those who did not receive corticosteroids. 
 
Our findings were robust when assessed using several different approaches. Results were consistent 
using the ATE, reflecting the overall population from which the sample was taken, and using the ATT, 
reflecting the population of patients who received corticosteroids. They were also consistent controlling 
for potential confounders such as demographics, phase of the pandemic, site prescribing patterns, 
comorbidities, and laboratory values.14 Furthermore, amongst patients age 70 and older, the mortality 
associated with corticosteroids appeared slightly greater in those on NC. Taken together, our findings 
suggest that the harms of corticosteroids – which become more apparent approximately 20 days after 
admission (Figure 3) – may outweigh benefits in hospitalized patients with COVID-19, particularly those 
who require no oxygen within 48 hours of admission. These findings may be under-estimated in studies 
where outcomes were assessed at 30-days and did not extend follow-up to 90-days.  
 
While we cannot rule out residual confounding, results are consistent with the RECOVERY trial where 
the benefit of dexamethasone also diminished for patients not on IMV, and may have suggested 
possible harm in those not requiring oxygen.1 Recent meta-analyses and observational studies have also 
reported greater benefit of corticosteroids in severe compared to more mild acute respiratory distress 
syndrome (ARDS).7,9 However, these studies did not stratify patients further by level of respiratory 
support during the initial 48 hours of hospitalization, separating those who did and did not require IRS. 
Instead, clinical guidelines such as those issued by the National Institutes of Health recommend 
initiation of corticosteroids in hospitalized COVID-19 patients on oxygen, without further distinguishing 
between low-flow NC and forms of IRS.20 Our findings raise a note of caution when considering potential 
“indication creep” in the real world for use of corticosteroids in patients who do not have moderate-
severe COVID-19 requiring IRS. Further randomized controlled trials of corticosteroids in patients with 
COVID-19 who are not on IRS may be warranted.   
 
From an implementation perspective, we found that uptake of corticosteroids for hospitalized COVID-19 
patients was rapid. By mid-July 2020 most facilities had increased the proportion of patients 
administered corticosteroids to over 90% of those who were on HFNC or IMV within 48 hours of 
admission. Initiation of corticosteroids later during hospitalization was infrequent and decreased over 
time. Sites also increased use of corticosteroids for patients with less severe COVID-19, including those 
not on oxygen at the time of initiation (Figure 2). Patients not on IRS in the initial 48 hours represent the 
majority of COVID-19 admissions in the cohort; thus, our findings have important clinical implications on 
the potential unintended consequences of widespread corticosteroid adoption for COVID-19. 
 
Even prior to COVID-19, the role of corticosteroids in lung infection has been uncertain. The impact of 
corticosteroids on patient outcomes has been inconsistent In other causes of ARDS including influenza 
and community-acquired pneumonia (CAP). In several viral pneumonias, corticosteroids were associated 
with greater risk of harm,21-23 although they appeared beneficial in the original severe acute respiratory 
syndrome.7,24 The net balance between benefit and harm of corticosteroids for pneumonia is not well 
understood and likely depends on multiple factors, including patient characteristics, heterogeneity in 
host response to infection, etiology of pneumonia, and time since onset of infection and ARDS.25-28 
While corticosteroids may decrease host inflammatory response with potential modulating effects to 
lung injury, they may also have harmful side effects or unintended consequences on adaptive immune 
responses that may be important to resolution of infection. We saw potentially an increased risk of 
mortality associated with corticosteroids in patients on NC who were over age 70. Whether this is due to 
differences in immune responses in older individuals and/or greater risk of unintended consequences 
from corticosteroids, such as secondary infections, requires further study.  
 
There remain additional unanswered questions regarding the timing of corticosteroids for patients 
hospitalized with COVID-19, particularly those not on IRS. When corticosteroids are initiated during the 
course of infection is likely important. For some patients, initiation within 48 hours of hospitalization 
may be too early in the course of disease and could impair viral clearance.29 While the majority of 
patients had positive SARS-CoV-2 testing within one day prior to hospitalization in our cohort, we do not 
know how long symptoms preceded a patient seeking medical attention and receiving SARS-CoV-2 
testing. The optimal formulation, dose and duration of corticosteroids also remain unclear, and if these 
should vary depending on severity of COVID-19.2-4,29  
 
There are several limitations to our study. First, the study was observational. While we used detailed 
clinical data that included measures reflecting illness severity in a large population that demonstrated 
excellent balance in propensity for treatment, residual confounding for severity of illness could have 
contributed to greater mortality in those exposed to corticosteroids. In addition, the effects associated 
with initial corticosteroids are difficult to disentangle from other therapies that may have been 
concomitantly received. Some laboratory results used as covariates could have occurred after 
corticosteroid exposure, as both were ascertained within 48 hours. However, this approach allowed an 
equal time window to detect worst results in patients exposed and unexposed to corticosteroids and the 
impact of corticosteroids on acute laboratory results was likely limited. Although respiratory support 
algorithms were manually reviewed and validated, some misclassification may have occurred. 
Nonetheless, the substantial separation in Kaplan-Meier mortality curves with increasing mortality with 
greater respiratory support supports the validity of this variable. We also cannot rule out that clinicians 
were aware of another indication for corticosteroids beyond COVID-19 in patients who were not on 
oxygen or were on NC, such as airway inflammation from obstructive lung disease. However, we 
excluded those on steroids prior to admission and patients on vasopressors within the initial 48 hours, 
as these patients were more likely have an alternative indication for steroids. Further, we did not assess 
dose of corticosteroids or calculate total duration of exposure by including discharge medications after 
index hospitalization. Most patients had an average length of inpatient corticosteroid treatment that 
matched their hospital length of stay, and very few received only one dose of a corticosteroid (<3%). 
Finally, our cohort consisted predominantly of male Veterans, but had excellent racial and geographic 
variability.  
 
In summary, we found that in patients with COVID-19 not on IRS in the first 48 hours of hospitalization, 
early corticosteroids were associated with increased 90-day mortality. Further, we failed to confirm a 
benefit of early corticosteroids to 90-day mortality in those on NC oxygen. These results were consistent 
in different analytic approaches that used real-world evidence with detailed clinical data in a large 
population to control for confounding, and remained robust in a variety of subgroup and sensitivity 
analyses. Our findings raise the possibility that harms of corticosteroids initiated within 48 hours of 
hospitalization may outweigh benefits in some patients with COVID-19 and less severe respiratory 
compromise, particularly in those who not on oxygen within 48 hours of hospital admission.  
  
Figure 1. Derivation of Study Population  
  
12,455 VA hospitalizations 
within 14 days after positive 
SARS-CoV-2 Test 3397 excluded (more than 1 may apply)
1619 < 48-hour length of stay
• 40 died
298 transfer in from another acute care
563 likely incidental positive test
• 323 no COVID-19 diagnosis
• 270 no medical service (i.e. nursing home, hospice, 
psychiatry or surgery only)
• 21 no inpatient medications
879 received systemic steroids before admission*
101 received hydroxychloroquine
356 admitted to site that did not use dexamethasone
9,058 stratified  by respiratory support (RS)
(no oxygen, nasal cannula (NC) only, other supplemental oxygen/non-
invasive ventilation,  high-flow NC, invasive mechanical ventilation)
3,406 (3404) received systemic 
corticosteroids within first 48 hours
598 (597) no oxygen 
2,808 (2807) NC only
6,825  no intensive RS    
3,025 no oxygen 
3,800 NC only
3,419 (3421) no systemic corticosteroids
within first 48 hours
2,427 (2428) no oxygen
992 (993) NC only
441 died <= 90 days from admission
69 no oxygen 
372 NC only
356 died <= 90 days from admission














A.             B. 
Figure 2. Unadjusted Kaplan Meier survival curves for 90-day mortality  (A) and proportion exposed to corticosteroids by respiratory support 
level over time (B). RECOVERY Trial corticosteroid results issued in press release on 16 June 2020.  
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Figure 3. IPTW Kaplan Meier survival curves for 90-day mortality by corticosteroid use among those on no oxygen or NC.  
IPTW = Inverse probability of treatment weighting 
NC = nasal cannula  
TABLE 1: Characteristics of patients stratified by highest oxygen support during first 48 hours of hospitalization for COVID-19 
 Oxygen Support first 48 hours 




Invasive Mechanical  
Ventilation  
Overall Cohort, n 9,058 3,025 3,800 813 1,194 226 
Demographics       
Age, n (%)       
<50 806 (9%) 332 (11%) 331 (9%) 52 (6%) 73 (6%) 18 (8%) 
50-59 1,081 (12%) 389 (13%) 470 (12%) 79 (10%) 121 (10%) 22 (10%) 
60-69 2,134 (24%) 692 (23%) 874 (23%) 202 (25%) 300 (25%) 66 (29%) 
70-79 3,259 (36%) 970 (32%) 1,397 (37%) 320 (39%) 479 (40%) 93 (41%) 
80+ 1,778 (20%) 642 (21%) 728 (19%) 160 (20%) 221 (19%) 27 (12%) 
Sex: Male, n (%) 8,606 (95%) 2,858 (94%) 3,594 (95%) 775 (95%) 1,163 (97%) 216 (96%) 
Race, n (%)       
White, non-Hispanic 4,989 (55%) 1,563 (52%) 2,121 (56%) 480 (59%) 704 (59%) 121 (54%) 
Black, non-Hispanic 2,426 (27%) 928 (31%) 985 (26%) 211 (26%) 258 (22%) 44 (19%) 
Hispanic 864 (10%) 276 (9%) 371 (10%) 57 (7%) 125 (10%) 35 (15%) 
Other 491 (5%) 152 (5%) 208 (5%) 46 (6%) 70 (6%) 15 (7%) 
Unknown 288 (3%) 106 (4%) 115 (3%) 19 (2%) 37 (3%) 11 (5%) 
Phase (Admission Date, 2020), n 
(%)       
1: June 7 - July 11 1,365 (15%) 483 (16%) 563 (15%) 103 (13%) 169 (14%) 47 (21%) 
2: July 12 - Aug. 15 1,590 (18%) 537 (18%) 695 (18%) 140 (17%) 186 (16%) 32 (14%) 
3: Aug. 16 - Oct. 17 1,908 (21%) 668 (22%) 792 (21%) 163 (20%) 229 (19%) 56 (25%) 
4: Oct. 18 - Dec. 5 4,195 (46%) 1,337 (44%) 1,750 (46%) 407 (50%) 610 (51%) 91 (40%) 
Selected Conditions       
Dementia, n (%) 1,193 (13%) 527 (17%) 429 (11%) 123 (15%) 99 (8%) 15 (7%) 
CHF, n (%) 1,886 (21%) 571 (19%) 810 (21%) 233 (29%) 233 (20%) 39 (17%) 
COPD/Asthma, n (%) 2,715 (30%) 729 (24%) 1,251 (33%) 296 (36%) 377 (32%) 62 (27%) 
Charlson Comorbidity Index, n (%)       
0 1,706 (19%) 634 (21%) 698 (18%) 98 (12%) 233 (20%) 43 (19%) 
1-2 2,868 (32%) 940 (31%) 1,216 (32%) 219 (27%) 409 (34%) 84 (37%) 
3-4 2,145 (24%) 660 (22%) 940 (25%) 224 (28%) 274 (23%) 47 (21%) 
5+ 2,339 (26%) 791 (26%) 946 (25%) 272 (33%) 278 (23%) 52 (23%) 
Medication Use       
Steroid, Any Systemic, n (%)       
First 48 Hours 5,165 (57%) 598 (20%) 2,808 (74%) 468 (58%) 1,083 (91%) 208 (92%) 
Later than 48 Hours 870 (10%) 363 (12%) 337 (9%) 115 (14%) 43 (4%) 12 (5%) 
None 3,023 (33%) 2,064 (68%) 655 (17%) 230 (28%) 68 (6%) 6 (3%) 
Dexamethasone, n (%)       
 Oxygen Support first 48 hours 




Invasive Mechanical  
Ventilation  
First 48 Hours 4,911 (54%) 511 (17%) 2,712 (71%) 430 (53%) 1,057 (89%) 201 (89%) 
Later than 48 Hours 875 (10%) 354 (12%) 344 (9%) 117 (14%) 45 (4%) 15 (7%) 
None 3,272 (36%) 2,160 (71%) 744 (20%) 266 (33%) 92 (8%) 10 (4%) 
Remdesivir, n (%)       
First 48 Hours 4,078 (45%) 434 (14%) 2,222 (58%) 340 (42%) 928 (78%) 154 (68%) 
Later than 48 Hours 911 (10%) 314 (10%) 398 (10%) 106 (13%) 72 (6%) 21 (9%) 
None 4,069 (45%) 2,277 (75%) 1,180 (31%) 367 (45%) 194 (16%) 51 (23%) 
Prophylactic Anticoagulant, n (%)       
First 48 Hours 5,020 (55%) 1,606 (53%) 2,180 (57%) 438 (54%) 666 (56%) 130 (58%) 
Later than 48 Hours 549 (6%) 175 (6%) 210 (6%) 53 (7%) 94 (8%) 17 (8%) 
None 3,489 (39%) 1,244 (41%) 1,410 (37%) 322 (40%) 434 (36%) 79 (35%) 
Intensive Care, n (%)       
First 48 Hours 2,006 (22%) 278 (9%) 583 (15%) 203 (25%) 735 (62%) 207 (92%) 
Later than 48 Hours 676 (7%) 124 (4%) 352 (9%) 76 (9%) 113 (9%) 11 (5%) 
None 6,376 (70%) 2,623 (87%) 2,865 (75%) 534 (66%) 346 (29%) 8 (4%) 
Vasopressors, n (%)       
First 48 Hours 188 ( 2.1%) 9 (0.3%) 19 ( 0.5%) 11 ( 1.4%) 27 ( 2.3%) 122 (54.0%) 
Later than 48 Hours 539 ( 6.0%) 47 (1.6%) 169 ( 4.4%) 44 ( 5.4%) 217 (18.2%) 62 (27.4%) 
None 8331 (92.0%) 2,969 (98.1%) 3612 (95.1%) 758 (93.2%) 950 (79.6%) 42 (18.6%) 
Intubation, n (%)       
First 48 Hours 226 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 226 (100%) 
Later than 48 Hours 492 (5%) 49 (2%) 161 (4%) 46 (6%) 236 (20%) 0 (0%) 
None 8,340 (92%) 2,976 (98%) 3,639 (96%) 767 (94%) 958 (80%) 0 (0%) 
Hospital Length of Stay, days, 
median (interquartile range) 6 (4 – 12) 5 (3 – 11) 6 (4 – 10) 6 (4 – 12) 10 (6 – 17) 16 (10 – 30) 
Mortality (unadjusted, cumulative 
incidence)       
30 Days, n (%) 1,151 (13%) 184 (6%) 375 (10%) 124 (15%) 360 (30%) 108 (48%) 
60 Days, n (%) 1,413 (16%) 247 (8%) 477 (13%) 164 (20%) 404 (34%) 121 (54%) 
90 Days, n (%) 1,512 (17%) 283 (9%) 514 (14%) 175 (22%) 416 (35%) 124 (55%) 
       
       
       
       
 
Table 2. Characteristics of patients without oxygen or on NC after inverse probability of treatment 
weighting (IPTW) for estimating the average treatment effect in the total population (ATE models) 
Corticosteroids 
Combined Cohort of patients without oxygen or on NC only 
No Yes SMD 
Cohort, n 5796.7 6144.2  
Age, (%)    
<50 514.4 ( 8.9) 572.8 ( 9.3) 0.004 
50-59 683.7 (11.8) 761.0 (12.4) 0.006 
60-69 1329.2 (22.9) 1390.5 (22.6) -0.003 
70-79 2055.2 (35.5) 2247.7 (36.6) 0.011 
80+ 1214.1 (20.9) 1172.2 (19.1) -0.019 
Sex: Male, (%) 5458.7 (94.2) 5808.7 (94.5) 0.004 
Race, (%)    
White, non-Hispanic 3011.8 (52.0) 3301.2 (53.7) 0.018 
Black, non-Hispanic 1759.4 (30.4) 1731.6 (28.2) -0.022 
Hispanic 516.5 ( 8.9) 577.9 ( 9.4) 0.005 
Other 317.7 ( 5.5) 330.8 ( 5.4) -0.001 
Unknown 191.4 ( 3.3) 202.9 ( 3.3) 0.000 
Phase (Admission Date) , (%)    
1: June 7 - July 11 1077.2 (18.6) 850.2 (13.8) -0.047 
2: July 12 - Aug. 15 1049.2 (18.1) 1165.3 (19.0) 0.009 
3: Aug. 16 - Oct. 17 1260.0 (21.7) 1290.7 (21.0) -0.007 
4: Oct. 18 - Dec. 5 2410.3 (41.6) 2838.0 (46.2) 0.046 
Site Dexamethasone Prescribing, (%)    
Low 1477.9 (25.5) 1227.7 (20.0) -0.055 
Medium 3565.1 (61.5) 3705.7 (60.3) -0.012 
High 753.7 (13.0) 1210.9 (19.7) 0.067 
Smoking Status, (%)    
Never Smoked 2008.6 (34.7) 2061.8 (33.6) -0.011 
Former Smoker 2382.6 (41.1) 2686.1 (43.7) 0.026 
Current Smoker 1315.7 (22.7) 1275.6 (20.8) -0.019 
Unknown 89.8 ( 1.5) 120.6 ( 2.0) 0.004 
AUDIT-C Score (%)    
0 3677.0 (63.4) 3870.0 (63.0) -0.004 
1 – 3 1236.9 (21.3) 1393.5 (22.7) 0.013 
4 – 7 351.7 ( 6.1) 348.8 ( 5.7) -0.004 
8 + 130.9 ( 2.3) 118.7 ( 1.9) -0.003 
Unknown 400.2 ( 6.9) 413.2 ( 6.7) -0.002 
  Comorbidities    
Myocardial Infarction (%) 491.5 ( 8.5) 468.9 ( 7.6) -0.008 
Congestive Heart Failure (%) 1257.0 (21.7) 1256.7 (20.5) -0.012 
Cerebrovascular Disease (%) 1005.1 (17.3) 988.3 (16.1) -0.013 
Dementia (%) 904.3 (15.6) 721.8 (11.7) -0.039 
Chronic Obstructive Pulmonary Disease (%) 1517.3 (26.2) 1889.6 (30.8) 0.046 
Rheumatoid Arthritis (%) 79.5 ( 1.4) 87.7 ( 1.4) 0.001 
Peptic ulcer (%) 133.3 ( 2.3) 135.0 ( 2.2) -0.001 
Liver disease, mild (%) 637.9 (11.0) 624.3 (10.2) -0.008 
Diabetes, Uncomplicated (%) 2707.6 (46.7) 2862.2 (46.6) -0.001 
Diabetes, Complicated (%) 1810.1 (31.2) 1773.0 (28.9) -0.024 
Hemi or paraplegia (%) 168.6 ( 2.9) 148.6 ( 2.4) -0.005 
Liver disease, moderate-severe (%) 95.4 ( 1.6) 98.0 ( 1.6) -0.001 
Metastatic cancer (%) 121.9 ( 2.1) 115.1 ( 1.9) -0.002 
HIV (%) 70.3 ( 1.2) 57.5 ( 0.9) -0.003 
Renal disease (%) 1567.4 (27.0) 1560.7 (25.4) -0.016 
Charlson Comorbidities Count (%)    
0 1122.3 (19.4) 1207.4 (19.7) 0.003 
1 - 2 1767.9 (30.5) 1953.9 (31.8) 0.013 
3 - 4 1327.6 (22.9) 1481.3 (24.1) 0.012 
Corticosteroids 
Combined Cohort of patients without oxygen or on NC only 
No Yes SMD 
5 + 1578.9 (27.2) 1501.7 (24.4) -0.028 
Number of Doctors (prior year) (%)    
0 2330.1 (40.2) 2475.4 (40.3) 0.001 
1 1588.7 (27.4) 1685.4 (27.4) 0.000 
2 - 4 1717.9 (29.6) 1835.7 (29.9) 0.002 
5 + 160.0 ( 2.8) 147.6 ( 2.4) -0.004 
Specialty clinics attended 
  Cardiology (%) 1512.0 (26.1) 1661.1 (27.0) 0.010 
Coagulation (%) 88.0 ( 1.5) 93.8 ( 1.5) 0.000 
Pacemaker (%) 232.5 ( 4.0) 220.8 ( 3.6) -0.004 
Dialysis (%) 98.7 ( 1.7) 99.8 ( 1.6) -0.001 
Gastoenterology (%) 508.1 ( 8.8) 586.5 ( 9.5) 0.008 
Hepatology (%) 183.2 ( 3.2) 146.2 ( 2.4) -0.008 
Homeless (%) 376.3 ( 6.5) 304.9 ( 5.0) -0.015 
Co-Medications    
Prophylactic Anticoagulants 1st 48 hours (%) 3164.0 (54.6) 3444.3 (56.1) 0.015 
Remdesivir, 1st 48 hours (%) 1714.5 (29.6) 2630.2 (42.8) 0.132 
Laboratory values    
Albumin, g/dL  (%)    
3.5 + 2125.2 (36.7) 2040.4 (33.2) -0.035 
3 - 3.49 1871.1 (32.3) 2103.8 (34.2) 0.020 
< 3 1527.9 (26.4) 1775.3 (28.9) 0.025 
Missing 272.5 ( 4.7) 224.8 ( 3.7) -0.010 
Alanine aminotransferase, IU/L (%)    
< 20 1678.7 (29.0) 1532.1 (24.9) -0.040 
20 - 39 2415.7 (41.7) 2621.7 (42.7) 0.010 
40 + 1494.2 (25.8) 1839.4 (29.9) 0.042 
Missing 208.1 ( 3.6) 151.1 ( 2.5) -0.011 
Asparate aminostransferase, IU/L (%)    
< 20 1054.7 (18.2) 829.8 (13.5) -0.047 
20 - 39 2670.2 (46.1) 2816.1 (45.8) -0.002 
40 + 2071.8 (35.7) 2498.3 (40.7) 0.049 
Creatinine, mg/dL (%)    
< 1.2 2671.7 (46.1) 2857.0 (46.5) 0.004 
1.2 – 1.99 2141.5 (36.9) 2265.1 (36.9) -0.001 
2 + 983.5 (17.0) 1022.1 (16.6) -0.003 
Missing 0.0 ( 0.0) 0.0 ( 0.0)  
Fibrosis-4 Index (%)    
< 1.45 1065.6 (18.4) 1062.8 (17.3) -0.011 
1.45 – 3.25 2393.0 (41.3) 2597.0 (42.3) 0.010 
3.25 + 2101.8 (36.3) 2325.3 (37.8) 0.016 
Missing 236.3 ( 4.1) 159.1 ( 2.6) -0.015 
Lactate, mmol/L (%)    
<1.2 1003.8 (17.3) 1075.5 (17.5) 0.002 
1.2 - <2.0 1510.3 (26.1) 1816.4 (29.6) 0.035 
  2.0+ 737.4 (12.7) 880.6 (14.3) 0.016 
Missing 2545.2 (43.9) 2371.8 (38.6) -0.053 
Platelet count per microL (%)    
150 or higher 3822.5 (65.9) 4050.8 (65.9) 0.000 
< 150 1964.6 (33.9) 2081.7 (33.9) 0.000 
Missing 9.6 ( 0.2) 11.7 ( 0.2) 0.000 
Total bilirubin, mg/dL (%)    
< 1 4395.1 (75.8) 4646.6 (75.6) -0.002 
1 - 1.2 489.1 ( 8.4) 558.8 ( 9.1) 0.007 
1.2 + 730.4 (12.6) 808.8 (13.2) 0.006 
Missing 182.1 ( 3.1) 130.1 ( 2.1) -0.010 
White Blood Count per microL (%)    
Corticosteroids 
Combined Cohort of patients without oxygen or on NC only 
No Yes SMD 
4-10 3243.2 (55.9) 3097.6 (50.4) -0.055 
<4 1622.3 (28.0) 1776.7 (28.9) 0.009 
>10 931.2 (16.1) 1269.8 (20.7) 0.046 
C-reactive protein measured (%) 3428.1 (59.1) 3883.6 (63.2) 0.041 
D-dimer measured (%) 4512.3 (77.8) 4998.2 (81.3) 0.035 
Vital Signs    
Highest Temperature (F) (%)    
< 99 1968.5 (34.0) 2001.3 (32.6) -0.014 
99 - 100 1389.2 (24.0) 1452.8 (23.6) -0.003 
100 - 102 1601.0 (27.6) 1769.6 (28.8) 0.012 
102 + 818.1 (14.1) 893.9 (14.5) 0.004 
Missing 19.9 ( 0.3) 26.7 ( 0.4) 0.001 
Mean Arterial Pressure, mmHg (%)    
< 60 141.0 ( 2.4) 118.5 ( 1.9) -0.005 
60 – 69 784.4 (13.5) 751.0 (12.2) -0.013 
70 – 89 3812.6 (65.8) 4141.8 (67.4) 0.016 
90 + 1049.4 (18.1) 1112.1 (18.1) 0.000 
Missing 9.3 ( 0.2) 20.8 ( 0.3) 0.002 
Lowest Oxygen Saturation (%)    
< 88 312.7 ( 5.4) 468.1 ( 7.6) 0.022 
88 - 92 2438.6 (42.1) 3022.9 (49.2) 0.071 
93 - 95 2191.5 (37.8) 2006.9 (32.7) -0.051 
96 + 733.5 (12.7) 513.5 ( 8.4) -0.043 
Missing 120.3 ( 2.1) 132.9 ( 2.2) 0.001 
    




Table 3. IPTW Cox Proportional Hazards Models for 90-day mortality associated with early 
corticosteroid exposure in patients hospitalized for COVID-19 among those not on IRS 
 No oxygen supplementation Nasal cannula 
Combined group: no 
oxygen plus NC 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Primary analysis 1.89 (1.33-2.68) 1.21 (0.94-1.57) 1.61 (1.33-1.94) 
Subgroup analyses    
Restricted to dexamethasone  2.03 (1.35-3.07) 1.23 (0.89-1.71) 1.57 (1.22-2.03) 
Excluding patients admitted to 
ICU in initial 48 hours 1.86 (1.22-2.83) 1.30 (0.95-1.78) 1.62 (1.28-2.06) 
Restricted to patients age 70 and 
older 1.91 (1.28-2.85) 1.40 (1.03-1.92) 1.65 (1.30-2.08) 
Models present the ATE (average treatment effect in entire population).   
CI = confidence interval 
HR = hazard ratio 
IPTW = inverse probability of treatment weighting  
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Supplemental Table 1. Propensity weighted pseudo populations and unweighted sample 
ATT 
Characteristics No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No No Yes SMD Yes No 
Cohort, n 2979.1 2108.3  2585.7 3755.7  5796.7 6144.2  
Age, (%)          
<50 324.5 (10.9) 192.7 ( 9.1) -0.018 205.9 ( 8.0) 339.7 ( 9.0) 0.011 514.4 ( 8.9) 572.8 ( 9.3) 0.004 
50-59 368.8 (12.4) 263.4 (12.5) 0.001 314.0 (12.1) 473.6 (12.6) 0.005 683.7 (11.8) 761.0 (12.4) 0.006 
60-69 686.9 (23.1) 536.7 (25.5) 0.024 569.7 (22.0) 842.4 (22.4) 0.004 1329.2 (22.9) 1390.5 (22.6) -0.003 
70-79 964.0 (32.4) 719.7 (34.1) 0.018 938.2 (36.3) 1384.5 (36.9) 0.006 2055.2 (35.5) 2247.7 (36.6) 0.011 
80+ 634.9 (21.3) 395.7 (18.8) -0.025 557.9 (21.6) 715.4 (19.0) -0.025 1214.1 (20.9) 1172.2 (19.1) -0.019 
Sex: Male, (%) 2811.8 (94.4) 2014.8 (95.6) 0.012 2438.8 (94.3) 3558.1 (94.7) 0.004 5458.7 (94.2) 5808.7 (94.5) 0.004 
Race, (%)          
White, non-Hispanic 1528.8 (51.3) 1028.0 (48.8) -0.026 1362.1 (52.7) 2078.5 (55.3) 0.027 3011.8 (52.0) 3301.2 (53.7) 0.018 
Black, non-Hispanic 943.3 (31.7) 686.9 (32.6) 0.009 728.0 (28.2) 984.7 (26.2) -0.019 1759.4 (30.4) 1731.6 (28.2) -0.022 
Hispanic 259.7 ( 8.7) 212.2 (10.1) 0.013 252.8 ( 9.8) 355.2 ( 9.5) -0.003 516.5 ( 8.9) 577.9 ( 9.4) 0.005 
Other 149.9 ( 5.0) 121.5 ( 5.8) 0.007 159.1 ( 6.2) 218.3 ( 5.8) -0.003 317.7 ( 5.5) 330.8 ( 5.4) -0.001 
Unknown 97.4 ( 3.3) 59.7 ( 2.8) -0.004 83.8 ( 3.2) 119.0 ( 3.2) -0.001 191.4 ( 3.3) 202.9 ( 3.3) 0.000 
Phase (Admission Date) , (%)          
1: June 7 - July 11 474.3 (15.9) 273.5 (13.0) -0.029 581.1 (22.5) 602.7 (16.0) -0.064 1077.2 (18.6) 850.2 (13.8) -0.047 
2: July 12 - Aug. 15 515.4 (17.3) 325.9 (15.5) -0.018 538.5 (20.8) 676.8 (18.0) -0.028 1049.2 (18.1) 1165.3 (19.0) 0.009 
3: Aug. 16 - Oct. 17 659.4 (22.1) 483.1 (22.9) 0.008 564.4 (21.8) 772.6 (20.6) -0.013 1260.0 (21.7) 1290.7 (21.0) -0.007 
4: Oct. 18 - Dec. 5 1330.1 (44.6) 1025.7 (48.6) 0.040 901.7 (34.9) 1703.6 (45.4) 0.105 2410.3 (41.6) 2838.0 (46.2) 0.046 
Site Dexamethasone Prescribing, (%)          
Low 768.0 (25.8) 365.1 (17.3) -0.085 684.2 (26.5) 719.1 (19.1) -0.073 1477.9 (25.5) 1227.7 (20.0) -0.055 
Medium 1811.7 (60.8) 1379.7 (65.4) 0.046 1510.0 (58.4) 2236.0 (59.5) 0.011 3565.1 (61.5) 3705.7 (60.3) -0.012 
High 399.5 (13.4) 363.5 (17.2) 0.038 391.5 (15.1) 800.5 (21.3) 0.062 753.7 (13.0) 1210.9 (19.7) 0.067 
Smoking Status, (%)          
Never Smoked 1042.9 (35.0) 761.9 (36.1) 0.011 907.6 (35.1) 1264.8 (33.7) -0.014 2008.6 (34.7) 2061.8 (33.6) -0.011 
Former Smoker 1149.4 (38.6) 867.1 (41.1) 0.025 1108.8 (42.9) 1705.5 (45.4) 0.025 2382.6 (41.1) 2686.1 (43.7) 0.026 
Current Smoker 718.6 (24.1) 452.5 (21.5) -0.027 527.7 (20.4) 721.5 (19.2) -0.012 1315.7 (22.7) 1275.6 (20.8) -0.019 
Unknown 68.3 ( 2.3) 26.7 ( 1.3) -0.010 41.6 ( 1.6) 63.9 ( 1.7) 0.001 89.8 ( 1.5) 120.6 ( 2.0) 0.004 
AUDIT-C Score (%)          
0 1836.1 (61.6) 1303.7 (61.8) 0.002 1690.4 (65.4) 2422.7 (64.5) -0.009 3677.0 (63.4) 3870.0 (63.0) -0.004 
1 – 3 599.9 (20.1) 435.8 (20.7) 0.005 579.4 (22.4) 872.6 (23.2) 0.008 1236.9 (21.3) 1393.5 (22.7) 0.013 
4 – 7 211.4 ( 7.1) 161.7 ( 7.7) 0.006 118.1 ( 4.6) 180.5 ( 4.8) 0.002 351.7 ( 6.1) 348.8 ( 5.7) -0.004 
8 + 92.9 ( 3.1) 53.8 ( 2.6) -0.006 44.7 ( 1.7) 59.2 ( 1.6) -0.002 130.9 ( 2.3) 118.7 ( 1.9) -0.003 
Unknown 238.9 ( 8.0) 153.3 ( 7.3) -0.007 153.1 ( 5.9) 220.8 ( 5.9) 0.000 400.2 ( 6.9) 413.2 ( 6.7) -0.002 
Comorbidities          
Myocardial Infarction (%) 247.1 ( 8.3) 138.3 ( 6.6) -0.017 230.3 ( 8.9) 310.2 ( 8.3) -0.006 491.5 ( 8.5) 468.9 ( 7.6) -0.008 
Congestive Heart Failure (%) 558.7 (18.8) 411.2 (19.5) 0.008 642.6 (24.9) 806.2 (21.5) -0.034 1257.0 (21.7) 1256.7 (20.5) -0.012 
Characteristics No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No No Yes SMD Yes No 
Cerebrovascular Disease (%) 534.4 (17.9) 332.8 (15.8) -0.022 451.3 (17.5) 626.0 (16.7) -0.008 1005.1 (17.3) 988.3 (16.1) -0.013 
Dementia (%) 517.0 (17.4) 270.8 (12.8) -0.045 375.2 (14.5) 439.1 (11.7) -0.028 904.3 (15.6) 721.8 (11.7) -0.039 
Chronic Obstructive Pulmonary Disease 
(%) 706.3 (23.7) 570.9 (27.1) 0.034 824.1 (31.9) 1226.3 (32.7) 0.008 1517.3 (26.2) 1889.6 (30.8) 0.046 
Rheumatoid Arthritis (%) 50.9 ( 1.7) 22.5 ( 1.1) -0.006 54.0 ( 2.1) 70.8 ( 1.9) -0.002 79.5 ( 1.4) 87.7 ( 1.4) 0.001 
Peptic ulcer (%) 78.9 ( 2.6) 46.9 ( 2.2) -0.004 50.8 ( 2.0) 87.9 ( 2.3) 0.004 133.3 ( 2.3) 135.0 ( 2.2) -0.001 
Liver disease, mild (%) 397.6 (13.3) 272.8 (12.9) -0.004 239.1 ( 9.2) 350.7 ( 9.3) 0.001 637.9 (11.0) 624.3 (10.2) -0.008 
Diabetes, Uncomplicated (%) 1327.3 (44.6) 972.6 (46.1) 0.016 1264.4 (48.9) 1834.9 (48.9) 0.000 2707.6 (46.7) 2862.2 (46.6) -0.001 
Diabetes, Complicated (%) 862.3 (28.9) 578.4 (27.4) -0.015 837.4 (32.4) 1128.6 (30.0) -0.023 1810.1 (31.2) 1773.0 (28.9) -0.024 
Hemi or para plegia (%) 94.4 ( 3.2) 49.0 ( 2.3) -0.008 74.6 ( 2.9) 85.3 ( 2.3) -0.006 168.6 ( 2.9) 148.6 ( 2.4) -0.005 
Liver disease, moderate-severe (%) 73.8 ( 2.5) 63.9 ( 3.0) 0.006 27.1 ( 1.0) 42.5 ( 1.1) 0.001 95.4 ( 1.6) 98.0 ( 1.6) -0.001 
Metastatic cancer (%) 62.3 ( 2.1) 23.3 ( 1.1) -0.010 32.3 ( 1.3) 63.3 ( 1.7) 0.004 121.9 ( 2.1) 115.1 ( 1.9) -0.002 
HIV (%) 39.4 ( 1.3) 29.1 ( 1.4) 0.001 39.0 ( 1.5) 51.2 ( 1.4) -0.001 70.3 ( 1.2) 57.5 ( 0.9) -0.003 
Renal disease (%) 735.1 (24.7) 537.2 (25.5) 0.008 729.4 (28.2) 964.6 (25.7) -0.025 1567.4 (27.0) 1560.7 (25.4) -0.016 
Charlson Comorbidities Count (%)          
0 621.0 (20.8) 448.5 (21.3) 0.004 485.5 (18.8) 689.1 (18.3) -0.004 1122.3 (19.4) 1207.4 (19.7) 0.003 
1 - 2 920.5 (30.9) 688.0 (32.6) 0.017 733.7 (28.4) 1184.0 (31.5) 0.032 1767.9 (30.5) 1953.9 (31.8) 0.013 
3 - 4 654.1 (22.0) 456.2 (21.6) -0.003 617.4 (23.9) 913.0 (24.3) 0.004 1327.6 (22.9) 1481.3 (24.1) 0.012 
5 + 783.5 (26.3) 515.6 (24.5) -0.018 749.1 (29.0) 969.6 (25.8) -0.032 1578.9 (27.2) 1501.7 (24.4) -0.028 
Number of Doctors (prior year) (%)          
0 1276.8 (42.9) 885.2 (42.0) -0.009 985.6 (38.1) 1430.6 (38.1) 0.000 2330.1 (40.2) 2475.4 (40.3) 0.001 
1 816.9 (27.4) 627.3 (29.8) 0.023 674.8 (26.1) 1043.7 (27.8) 0.017 1588.7 (27.4) 1685.4 (27.4) 0.000 
2 - 4 812.5 (27.3) 555.7 (26.4) -0.009 850.5 (32.9) 1196.5 (31.9) -0.010 1717.9 (29.6) 1835.7 (29.9) 0.002 
5 + 72.9 ( 2.4) 40.1 ( 1.9) -0.005 74.8 ( 2.9) 84.9 ( 2.3) -0.006 160.0 ( 2.8) 147.6 ( 2.4) -0.004 
Specialty clinics attended 
Cardiology (%) 732.6 (24.6) 531.3 (25.2) 0.006 741.9 (28.7) 1059.3 (28.2) -0.005 1512.0 (26.1) 1661.1 (27.0) 0.010 
Coagulation (%) 47.5 ( 1.6) 46.8 ( 2.2) 0.006 40.3 ( 1.6) 49.8 ( 1.3) -0.002 88.0 ( 1.5) 93.8 ( 1.5) 0.000 
Pacemaker (%) 112.6 ( 3.8) 115.5 ( 5.5) 0.017 92.3 ( 3.6) 115.7 ( 3.1) -0.005 232.5 ( 4.0) 220.8 ( 3.6) -0.004 
Dialysis (%) 34.9 ( 1.2) 21.2 ( 1.0) -0.002 70.4 ( 2.7) 66.6 ( 1.8) -0.010 98.7 ( 1.7) 99.8 ( 1.6) -0.001 
Gastoenterology (%) 256.1 ( 8.6) 175.1 ( 8.3) -0.003 234.8 ( 9.1) 368.2 ( 9.8) 0.007 508.1 ( 8.8) 586.5 ( 9.5) 0.008 
Hepatology (%) 105.7 ( 3.5) 67.7 ( 3.2) -0.003 77.4 ( 3.0) 94.7 ( 2.5) -0.005 183.2 ( 3.2) 146.2 ( 2.4) -0.008 
Homeless (%) 231.8 ( 7.8) 148.3 ( 7.0) -0.007 127.0 ( 4.9) 141.8 ( 3.8) -0.011 376.3 ( 6.5) 304.9 ( 5.0) -0.015 
Co-medications          
Prophylactic Anticoagulants 1597.7 (53.6) 1127.2 (53.5) -0.002 1488.4 (57.6) 2171.8 (57.8) 0.003 3164.0 (54.6) 3444.3 (56.1) 0.015 
Remdesivir, 1st 48 hours (%) 433.7 (14.6) 439.7 (20.9) 0.063 999.8 (38.7) 2174.3 (57.9) 0.192 1714.5 (29.6) 2630.2 (42.8) 0.132 
Laboratory Results          
Albumin, g/dL  (%)          
3.5 + 1267.1 (42.5) 770.3 (36.5) -0.060 795.3 (30.8) 1084.5 (28.9) -0.019 2125.2 (36.7) 2040.4 (33.2) -0.035 
3 - 3.49 924.4 (31.0) 728.9 (34.6) 0.035 878.8 (34.0) 1348.7 (35.9) 0.019 1871.1 (32.3) 2103.8 (34.2) 0.020 
< 3 622.6 (20.9) 529.5 (25.1) 0.042 811.5 (31.4) 1199.6 (31.9) 0.006 1527.9 (26.4) 1775.3 (28.9) 0.025 
Missing 165.0 ( 5.5) 79.6 ( 3.8) -0.018 100.1 ( 3.9) 122.9 ( 3.3) -0.006 272.5 ( 4.7) 224.8 ( 3.7) -0.010 
Alanine aminotransferase, IU/L (%)          
< 20 949.8 (31.9) 596.0 (28.3) -0.036 656.3 (25.4) 853.0 (22.7) -0.027 1678.7 (29.0) 1532.1 (24.9) -0.040 
20 - 39 1155.8 (38.8) 865.1 (41.0) 0.022 1137.9 (44.0) 1638.7 (43.6) -0.004 2415.7 (41.7) 2621.7 (42.7) 0.010 
40 + 731.2 (24.5) 613.5 (29.1) 0.046 714.2 (27.6) 1184.6 (31.5) 0.039 1494.2 (25.8) 1839.4 (29.9) 0.042 
Characteristics No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No No Yes SMD Yes No 
Missing 142.3 ( 4.8) 33.6 ( 1.6) -0.032 77.2 ( 3.0) 79.4 ( 2.1) -0.009 208.1 ( 3.6) 151.1 ( 2.5) -0.011 
Asparate aminostransferase, IU/L (%)          
< 20 699.1 (23.5) 272.4 (12.9) -0.105 331.1 (12.8) 399.0 (10.6) -0.022 1054.7 (18.2) 829.8 (13.5) -0.047 
20 - 39 1372.6 (46.1) 1075.9 (51.0) 0.050 1166.3 (45.1) 1679.2 (44.7) -0.004 2670.2 (46.1) 2816.1 (45.8) -0.002 
40 + 907.4 (30.5) 760.0 (36.0) 0.056 1088.4 (42.1) 1677.6 (44.7) 0.026 2071.8 (35.7) 2498.3 (40.7) 0.049 
Creatinine, mg/dL (%)          
< 1.2 1499.4 (50.3) 967.2 (45.9) -0.045 1108.0 (42.9) 1704.5 (45.4) 0.025 2671.7 (46.1) 2857.0 (46.5) 0.004 
1.2 – 1.99 1035.8 (34.8) 811.3 (38.5) 0.037 992.1 (38.4) 1432.2 (38.1) -0.002 2141.5 (36.9) 2265.1 (36.9) -0.001 
2 + 432.9 (14.5) 329.8 (15.6) 0.011 485.6 (18.8) 619.0 (16.5) -0.023 983.5 (17.0) 1022.1 (16.6) -0.003 
Missing 11.0 ( 0.4) 0.0 ( 0.0) -0.004 0.0 ( 0.0) 0.0 ( 0.0)  0.0 ( 0.0) 0.0 ( 0.0)  
Fibrosis-4 Index (%)          
< 1.45 686.8 (23.1) 439.5 (20.8) -0.022 353.2 (13.7) 569.2 (15.2) 0.015 1065.6 (18.4) 1062.8 (17.3) -0.011 
1.45 – 3.25 1204.6 (40.4) 837.1 (39.7) -0.007 1067.9 (41.3) 1644.5 (43.8) 0.025 2393.0 (41.3) 2597.0 (42.3) 0.010 
3.25 + 928.5 (31.2) 798.1 (37.9) 0.067 1083.7 (41.9) 1456.9 (38.8) -0.031 2101.8 (36.3) 2325.3 (37.8) 0.016 
Missing 159.2 ( 5.3) 33.6 ( 1.6) -0.038 81.0 ( 3.1) 85.1 ( 2.3) -0.009 236.3 ( 4.1) 159.1 ( 2.6) -0.015 
Lactate, mmol/L (%)          
1_1.2 493.0 (16.5) 441.7 (21.0) 0.044 455.4 (17.6) 695.1 (18.5) 0.009 1003.8 (17.3) 1075.5 (17.5) 0.002 
2_1.2LT2 682.6 (22.9) 558.3 (26.5) 0.036 713.6 (27.6) 1170.2 (31.2) 0.036 1510.3 (26.1) 1816.4 (29.6) 0.035 
3_GE2 348.1 (11.7) 312.3 (14.8) 0.031 385.0 (14.9) 559.1 (14.9) 0.000 737.4 (12.7) 880.6 (14.3) 0.016 
Missing 1455.5 (48.9) 796.0 (37.8) -0.111 1031.7 (39.9) 1331.3 (35.4) -0.045 2545.2 (43.9) 2371.8 (38.6) -0.053 
Platelet count per microL (%)          
150 or higher 2019.9 (67.8) 1370.8 (65.0) -0.028 1636.0 (63.3) 2488.6 (66.3) 0.030 3822.5 (65.9) 4050.8 (65.9) 0.000 
< 150 943.2 (31.7) 737.4 (35.0) 0.033 946.9 (36.6) 1262.6 (33.6) -0.030 1964.6 (33.9) 2081.7 (33.9) 0.000 
Missing 16.0 ( 0.5) 0.0 ( 0.0) -0.005 2.9 ( 0.1) 4.5 ( 0.1) 0.000 9.6 ( 0.2) 11.7 ( 0.2) 0.000 
Total bilirubin, mg/dL (%)          
< 1 2268.0 (76.1) 1624.2 (77.0) 0.009 1978.0 (76.5) 2841.7 (75.7) -0.008 4395.1 (75.8) 4646.6 (75.6) -0.002 
1 - 1.2 218.7 ( 7.3) 180.6 ( 8.6) 0.012 228.2 ( 8.8) 354.7 ( 9.4) 0.006 489.1 ( 8.4) 558.8 ( 9.1) 0.007 
1.2 + 368.0 (12.4) 281.1 (13.3) 0.010 307.6 (11.9) 487.2 (13.0) 0.011 730.4 (12.6) 808.8 (13.2) 0.006 
Missing 124.4 ( 4.2) 22.3 ( 1.1) -0.031 71.9 ( 2.8) 72.2 ( 1.9) -0.009 182.1 ( 3.1) 130.1 ( 2.1) -0.010 
White Blood Count per microL (%)          
4-10 1746.6 (58.6) 1082.6 (51.3) -0.073 1378.3 (53.3) 1818.5 (48.4) -0.049 3243.2 (55.9) 3097.6 (50.4) -0.055 
<4 803.4 (27.0) 653.7 (31.0) 0.040 769.2 (29.7) 1095.3 (29.2) -0.006 1622.3 (28.0) 1776.7 (28.9) 0.009 
>10 429.1 (14.4) 372.0 (17.6) 0.032 438.2 (16.9) 841.9 (22.4) 0.055 931.2 (16.1) 1269.8 (20.7) 0.046 
C-reactive protein measured (%) 1689.4 (56.7) 1364.5 (64.7) 0.080 1550.1 (59.9) 2386.3 (63.5) 0.036 3428.1 (59.1) 3883.6 (63.2) 0.041 
D-dimer measured (%) 2184.7 (73.3) 1657.5 (78.6) 0.053 2106.3 (81.5) 3153.8 (84.0) 0.025 4512.3 (77.8) 4998.2 (81.3) 0.035 
Vital Signs          
Highest Temperature (F) (%)          
< 99 1226.6 (41.2) 832.8 (39.5) -0.017 684.9 (26.5) 1071.6 (28.5) 0.020 1968.5 (34.0) 2001.3 (32.6) -0.014 
99 - 100 735.0 (24.7) 479.8 (22.8) -0.019 542.6 (21.0) 846.3 (22.5) 0.015 1389.2 (24.0) 1452.8 (23.6) -0.003 
100 - 102 693.4 (23.3) 522.8 (24.8) 0.015 869.7 (33.6) 1231.0 (32.8) -0.009 1601.0 (27.6) 1769.6 (28.8) 0.012 
102 + 314.2 (10.5) 267.2 (12.7) 0.021 478.5 (18.5) 591.4 (15.7) -0.028 818.1 (14.1) 893.9 (14.5) 0.004 
Missing 9.8 ( 0.3) 5.8 ( 0.3) -0.001 9.9 ( 0.4) 15.4 ( 0.4) 0.000 19.9 ( 0.3) 26.7 ( 0.4) 0.001 
Characteristics No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No No Yes SMD Yes No 
Mean Arterial Pressure, mmHg (%)          
< 60 70.8 ( 2.4) 53.4 ( 2.5) 0.002 61.1 ( 2.4) 72.9 ( 1.9) -0.004 141.0 ( 2.4) 118.5 ( 1.9) -0.005 
60 – 69 365.0 (12.3) 205.2 ( 9.7) -0.025 387.6 (15.0) 509.2 (13.6) -0.014 784.4 (13.5) 751.0 (12.2) -0.013 
70 – 89 1954.5 (65.6) 1416.8 (67.2) 0.016 1721.5 (66.6) 2531.4 (67.4) 0.008 3812.6 (65.8) 4141.8 (67.4) 0.016 
90 + 582.2 (19.5) 431.2 (20.5) 0.009 407.1 (15.7) 630.2 (16.8) 0.010 1049.4 (18.1) 1112.1 (18.1) 0.000 
Missing 6.6 ( 0.2) 1.7 ( 0.1) -0.001 8.5 ( 0.3) 12.1 ( 0.3) 0.000 9.3 ( 0.2) 20.8 ( 0.3) 0.002 
Lowest Oxygen Saturation (%)          
< 88 43.0 ( 1.4) 25.2 ( 1.2) -0.002 245.8 ( 9.5) 415.6 (11.1) 0.016 312.7 ( 5.4) 468.1 ( 7.6) 0.022 
88 - 92 887.9 (29.8) 707.3 (33.6) 0.037 1410.9 (54.6) 2170.9 (57.8) 0.032 2438.6 (42.1) 3022.9 (49.2) 0.071 
93 - 95 1415.5 (47.5) 997.6 (47.3) -0.002 727.3 (28.1) 896.6 (23.9) -0.043 2191.5 (37.8) 2006.9 (32.7) -0.051 
96 + 564.1 (18.9) 307.0 (14.6) -0.044 156.6 ( 6.1) 193.7 ( 5.2) -0.009 733.5 (12.7) 513.5 ( 8.4) -0.043 
Missing 68.6 ( 2.3) 71.2 ( 3.4) 0.011 45.1 ( 1.7) 78.9 ( 2.1) 0.004 120.3 ( 2.1) 132.9 ( 2.2) 0.001 
 
ATT 
Characteristics No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No No Yes SMD Yes No 
Cohort, n 452.7 595.0  1638.9 2793.0  2200.7 3388.0  
Age, (%)          
<50 39.7 ( 8.8) 59.0 ( 9.9) 0.011 138.8 ( 8.5) 261.0 ( 9.3) 0.009 177.4 ( 8.1) 320.0 ( 9.4) 0.014 
50-59 60.0 (13.3) 90.0 (15.1) 0.019 192.7 (11.8) 344.0 (12.3) 0.006 262.4 (11.9) 434.0 (12.8) 0.009 
60-69 113.7 (25.1) 138.0 (23.2) -0.019 360.3 (22.0) 647.0 (23.2) 0.012 496.8 (22.6) 785.0 (23.2) 0.006 
70-79 150.3 (33.2) 195.0 (32.8) -0.004 611.7 (37.3) 1048.0 (37.5) 0.002 802.7 (36.5) 1243.0 (36.7) 0.002 
80+ 88.9 (19.6) 113.0 (19.0) -0.007 335.5 (20.5) 493.0 (17.7) -0.028 461.4 (21.0) 606.0 (17.9) -0.031 
Sex: Male, (%) 430.0 (95.0) 562.0 (94.5) -0.005 1545.1 (94.3) 2644.0 (94.7) 0.004 2069.5 (94.0) 3206.0 (94.6) 0.006 
Race, (%)          
White, non-Hispanic 241.0 (53.2) 321.0 (53.9) 0.007 865.2 (52.8) 1589.0 (56.9) 0.041 1174.2 (53.4) 1910.0 (56.4) 0.030 
Black, non-Hispanic 134.0 (29.6) 159.0 (26.7) -0.029 438.4 (26.7) 678.0 (24.3) -0.025 612.6 (27.8) 837.0 (24.7) -0.031 
Hispanic 41.5 ( 9.2) 61.0 (10.3) 0.011 175.6 (10.7) 290.0 (10.4) -0.003 209.1 ( 9.5) 351.0 (10.4) 0.009 
Other 22.8 ( 5.0) 28.0 ( 4.7) -0.003 104.0 ( 6.3) 152.0 ( 5.4) -0.009 140.7 ( 6.4) 180.0 ( 5.3) -0.011 
Unknown 13.3 ( 2.9) 26.0 ( 4.4) 0.014 55.8 ( 3.4) 84.0 ( 3.0) -0.004 64.1 ( 2.9) 110.0 ( 3.2) 0.003 
Phase (Admission Date) , (%)          
1: June 7 - July 11 52.3 (11.6) 51.0 ( 8.6) -0.030 294.7 (18.0) 270.0 ( 9.7) -0.083 361.2 (16.4) 321.0 ( 9.5) -0.069 
2: July 12 - Aug. 15 63.6 (14.1) 79.0 (13.3) -0.008 343.2 (20.9) 490.0 (17.5) -0.034 380.2 (17.3) 569.0 (16.8) -0.005 
3: Aug. 16 - Oct. 17 100.9 (22.3) 139.0 (23.4) 0.011 368.3 (22.5) 587.0 (21.0) -0.015 457.7 (20.8) 726.0 (21.4) 0.006 
4: Oct. 18 - Dec. 5 235.9 (52.1) 326.0 (54.8) 0.027 632.7 (38.6) 1446.0 (51.8) 0.132 1001.6 (45.5) 1772.0 (52.3) 0.068 
Site Dexamethasone Prescribing, (%)          
Low 79.3 (17.5) 84.0 (14.1) -0.034 392.3 (23.9) 421.0 (15.1) -0.089 481.9 (21.9) 505.0 (14.9) -0.070 
Medium 290.3 (64.1) 358.0 (60.2) -0.040 964.2 (58.8) 1665.0 (59.6) 0.008 1353.7 (61.5) 2023.0 (59.7) -0.018 
High 83.0 (18.3) 153.0 (25.7) 0.074 282.4 (17.2) 707.0 (25.3) 0.081 365.1 (16.6) 860.0 (25.4) 0.088 
Smoking Status, (%)           
Characteristics No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No No Yes SMD Yes No 
Never Smoked 157.4 (34.8) 203.0 (34.1) -0.007 581.8 (35.5) 939.0 (33.6) -0.019 782.8 (35.6) 1142.0 (33.7) -0.019 
Former Smoker 188.9 (41.7) 269.0 (45.2) 0.035 720.5 (44.0) 1305.0 (46.7) 0.028 979.9 (44.5) 1574.0 (46.5) 0.019 
Current Smoker 99.6 (22.0) 112.0 (18.8) -0.032 323.2 (19.7) 506.0 (18.1) -0.016 415.3 (18.9) 618.0 (18.2) -0.006 
Unknown 6.8 ( 1.5) 11.0 ( 1.8) 0.004 13.5 ( 0.8) 43.0 ( 1.5) 0.007 22.8 ( 1.0) 54.0 ( 1.6) 0.006 
AUDIT-C Score (%)          
0 280.2 (61.9) 369.0 (62.0) 0.001 1068.2 (65.2) 1767.0 (63.3) -0.019 1413.4 (64.2) 2136.0 (63.0) -0.012 
1 – 3 94.0 (20.8) 132.0 (22.2) 0.014 389.1 (23.7) 674.0 (24.1) 0.004 501.8 (22.8) 806.0 (23.8) 0.010 
4 – 7 29.7 ( 6.6) 34.0 ( 5.7) -0.009 82.1 ( 5.0) 147.0 ( 5.3) 0.003 132.4 ( 6.0) 181.0 ( 5.3) -0.007 
8 + 11.9 ( 2.6) 15.0 ( 2.5) -0.001 24.6 ( 1.5) 43.0 ( 1.5) 0.000 29.9 ( 1.4) 58.0 ( 1.7) 0.004 
Unknown 36.9 ( 8.1) 45.0 ( 7.6) -0.006 74.9 ( 4.6) 162.0 ( 5.8) 0.012 123.2 ( 5.6) 207.0 ( 6.1) 0.005 
Comorbidities          
Myocardial Infarction (%) 30.4 ( 6.7) 36.0 ( 6.1) -0.007 144.2 ( 8.8) 216.0 ( 7.7) -0.011 183.4 ( 8.3) 252.0 ( 7.4) -0.009 
Congestive Heart Failure (%) 83.8 (18.5) 102.0 (17.1) -0.014 381.8 (23.3) 534.0 (19.1) -0.042 495.4 (22.5) 636.0 (18.8) -0.037 
Cerebrovascular Disease (%) 66.4 (14.7) 79.0 (13.3) -0.014 271.0 (16.5) 418.0 (15.0) -0.016 344.9 (15.7) 497.0 (14.7) -0.010 
Dementia (%) 47.8 (10.6) 59.0 ( 9.9) -0.007 207.7 (12.7) 252.0 ( 9.0) -0.036 268.3 (12.2) 311.0 ( 9.2) -0.030 
Chronic Obstructive Pulmonary Disease 
(%) 118.9 (26.3) 168.0 (28.2) 0.020 530.1 (32.3) 923.0 (33.0) 0.007 615.9 (28.0) 1091.0 (32.2) 0.042 
Rheumatoid Arthritis (%) 5.8 ( 1.3) 9.0 ( 1.5) 0.002 40.0 ( 2.4) 49.0 ( 1.8) -0.007 34.5 ( 1.6) 58.0 ( 1.7) 0.001 
Peptic ulcer (%) 7.9 ( 1.7) 9.0 ( 1.5) -0.002 27.8 ( 1.7) 55.0 ( 2.0) 0.003 39.2 ( 1.8) 64.0 ( 1.9) 0.001 
Liver disease, mild (%) 53.6 (11.8) 66.0 (11.1) -0.008 141.9 ( 8.7) 265.0 ( 9.5) 0.008 206.1 ( 9.4) 331.0 ( 9.8) 0.004 
Diabetes, Uncomplicated (%) 207.8 (45.9) 278.0 (46.7) 0.008 806.5 (49.2) 1369.0 (49.0) -0.002 1072.6 (48.7) 1647.0 (48.6) -0.001 
Diabetes, Complicated (%) 132.1 (29.2) 168.0 (28.2) -0.010 530.6 (32.4) 819.0 (29.3) -0.031 679.9 (30.9) 987.0 (29.1) -0.018 
Hemi or paraplegia (%) 11.4 ( 2.5) 10.0 ( 1.7) -0.008 38.6 ( 2.4) 52.0 ( 1.9) -0.005 50.5 ( 2.3) 62.0 ( 1.8) -0.005 
Liver disease, moderate-severe (%) 8.6 ( 1.9) 9.0 ( 1.5) -0.004 14.1 ( 0.9) 32.0 ( 1.1) 0.003 28.4 ( 1.3) 41.0 ( 1.2) -0.001 
Metastatic cancer (%) 6.3 ( 1.4) 6.0 ( 1.0) -0.004 18.3 ( 1.1) 46.0 ( 1.6) 0.005 49.9 ( 2.3) 52.0 ( 1.5) -0.007 
HIV (%) 7.4 ( 1.6) 10.0 ( 1.7) 0.000 26.9 ( 1.6) 20.0 ( 0.7) -0.009 27.3 ( 1.2) 30.0 ( 0.9) -0.004 
Renal disease (%) 113.0 (25.0) 140.0 (23.5) -0.014 456.8 (27.9) 656.0 (23.5) -0.044 599.0 (27.2) 796.0 (23.5) -0.037 
Charlson Comorbidities Count (%)          
0 92.5 (20.4) 134.0 (22.5) 0.021 314.0 (19.2) 518.0 (18.5) -0.006 426.0 (19.4) 652.0 (19.2) -0.001 
1 - 2 150.2 (33.2) 200.0 (33.6) 0.004 469.4 (28.6) 934.0 (33.4) 0.048 692.5 (31.5) 1134.0 (33.5) 0.020 
3 - 4 106.0 (23.4) 131.0 (22.0) -0.014 392.1 (23.9) 702.0 (25.1) 0.012 484.5 (22.0) 833.0 (24.6) 0.026 
5 + 104.1 (23.0) 130.0 (21.8) -0.011 463.4 (28.3) 639.0 (22.9) -0.054 597.7 (27.2) 769.0 (22.7) -0.045 
Number of Doctors (prior year) (%)          
0 185.8 (41.1) 250.0 (42.0) 0.010 604.6 (36.9) 1075.0 (38.5) 0.016 842.3 (38.3) 1325.0 (39.1) 0.008 
1 138.4 (30.6) 182.0 (30.6) 0.000 440.5 (26.9) 780.0 (27.9) 0.010 610.1 (27.7) 962.0 (28.4) 0.007 
2 - 4 121.6 (26.9) 155.0 (26.1) -0.008 549.1 (33.5) 879.0 (31.5) -0.020 683.3 (31.0) 1034.0 (30.5) -0.005 
5 + 6.9 ( 1.5) 8.0 ( 1.3) -0.002 44.7 ( 2.7) 59.0 ( 2.1) -0.006 65.0 ( 3.0) 67.0 ( 2.0) -0.010 
Specialty clinics attended 
  Cardiology (%) 109.1 (24.1) 147.0 (24.7) 0.006 461.5 (28.2) 759.0 (27.2) -0.010 599.5 (27.2) 906.0 (26.7) -0.005 
Coagulation (%) 9.5 ( 2.1) 13.0 ( 2.2) 0.001 20.2 ( 1.2) 31.0 ( 1.1) -0.001 30.0 ( 1.4) 44.0 ( 1.3) -0.001 
Pacemaker (%) 15.2 ( 3.4) 20.0 ( 3.4) 0.000 45.2 ( 2.8) 70.0 ( 2.5) -0.002 81.6 ( 3.7) 90.0 ( 2.7) -0.011 
Dialysis (%) 3.9 ( 0.9) 5.0 ( 0.8) 0.000 38.2 ( 2.3) 33.0 ( 1.2) -0.012 35.7 ( 1.6) 38.0 ( 1.1) -0.005 
Gastoenterology (%) 41.7 ( 9.2) 61.0 (10.3) 0.010 150.7 ( 9.2) 292.0 (10.5) 0.013 216.0 ( 9.8) 353.0 (10.4) 0.006 
Hepatology (%) 9.7 ( 2.2) 10.0 ( 1.7) -0.005 47.3 ( 2.9) 64.0 ( 2.3) -0.006 59.2 ( 2.7) 74.0 ( 2.2) -0.005 
Homeless (%) 27.1 ( 6.0) 30.0 ( 5.0) -0.009 70.7 ( 4.3) 93.0 ( 3.3) -0.010 112.4 ( 5.1) 123.0 ( 3.6) -0.015 
Co-medications          
Characteristics No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No No Yes SMD Yes No 
Prophylactic Anticoagulants 248.2 (54.8) 332.0 (55.8) 0.010 983.7 (60.0) 1643.0 (58.8) -0.012 1231.8 (56.0) 1975.0 (58.3) 0.023 
Remdesivir, 1st 48 hours (%) 124.3 (27.5) 257.0 (43.2) 0.157 826.8 (50.4) 2001.0 (71.6) 0.212 1087.6 (49.4) 2258.0 (66.6) 0.172 
Laboratory Results          
Albumin, g/dL  (%)          
3.5 + 174.5 (38.6) 218.0 (36.6) -0.019 498.7 (30.4) 781.0 (28.0) -0.025 677.5 (30.8) 999.0 (29.5) -0.013 
3 - 3.49 151.9 (33.5) 203.0 (34.1) 0.006 551.1 (33.6) 1005.0 (36.0) 0.024 773.8 (35.2) 1208.0 (35.7) 0.005 
< 3 107.9 (23.8) 151.0 (25.4) 0.015 537.1 (32.8) 928.0 (33.2) 0.005 680.4 (30.9) 1079.0 (31.8) 0.009 
Missing 18.4 ( 4.1) 23.0 ( 3.9) -0.002 51.9 ( 3.2) 79.0 ( 2.8) -0.003 69.0 ( 3.1) 102.0 ( 3.0) -0.001 
Alanine aminotransferase, IU/L (%)          
< 20 129.5 (28.6) 148.0 (24.9) -0.037 370.4 (22.6) 578.0 (20.7) -0.019 540.9 (24.6) 726.0 (21.4) -0.031 
20 - 39 187.3 (41.4) 242.0 (40.7) -0.007 737.3 (45.0) 1201.0 (43.0) -0.020 936.1 (42.5) 1443.0 (42.6) 0.001 
40 + 129.6 (28.6) 199.0 (33.4) 0.048 502.2 (30.6) 977.0 (35.0) 0.043 686.6 (31.2) 1176.0 (34.7) 0.035 
Missing 6.3 ( 1.4) 6.0 ( 1.0) -0.004 29.1 ( 1.8) 37.0 ( 1.3) -0.004 37.1 ( 1.7) 43.0 ( 1.3) -0.004 
Asparate aminostransferase, IU/L (%)          
< 20 61.7 (13.6) 65.0 (10.9) -0.027 139.2 ( 8.5) 218.0 ( 7.8) -0.007 225.0 (10.2) 283.0 ( 8.4) -0.019 
20 - 39 218.0 (48.2) 279.0 (46.9) -0.013 741.6 (45.3) 1218.0 (43.6) -0.016 1025.4 (46.6) 1497.0 (44.2) -0.024 
40 + 172.9 (38.2) 251.0 (42.2) 0.040 758.1 (46.3) 1357.0 (48.6) 0.023 950.4 (43.2) 1608.0 (47.5) 0.043 
Creatinine, mg/dL (%)          
< 1.2 206.5 (45.6) 277.0 (46.6) 0.009 700.3 (42.7) 1324.0 (47.4) 0.047 965.0 (43.9) 1601.0 (47.3) 0.034 
1.2 – 1.99 179.4 (39.6) 244.0 (41.0) 0.014 632.4 (38.6) 1048.0 (37.5) -0.011 861.5 (39.1) 1292.0 (38.1) -0.010 
2 + 66.8 (14.8) 74.0 (12.4) -0.023 306.2 (18.7) 421.0 (15.1) -0.036 374.1 (17.0) 495.0 (14.6) -0.024 
Missing 0.0 ( 0.0) 0.0 ( 0.0) 0.000 0.0 ( 0.0) 0.0 ( 0.0)  0.0 ( 0.0) 0.0 ( 0.0)  
Fibrosis-4 Index (%)          
< 1.45 96.4 (21.3) 129.0 (21.7) 0.004 197.6 (12.1) 411.0 (14.7) 0.027 335.2 (15.2) 540.0 (15.9) 0.007 
1.45 – 3.25 178.7 (39.5) 239.0 (40.2) 0.007 692.4 (42.2) 1260.0 (45.1) 0.029 878.7 (39.9) 1499.0 (44.2) 0.043 
3.25 + 171.1 (37.8) 220.0 (37.0) -0.008 718.1 (43.8) 1081.0 (38.7) -0.051 948.1 (43.1) 1301.0 (38.4) -0.047 
Missing 6.6 ( 1.5) 7.0 ( 1.2) -0.003 30.8 ( 1.9) 41.0 ( 1.5) -0.004 38.7 ( 1.8) 48.0 ( 1.4) -0.003 
Lactate, mmol/L (%)          
1_1.2 86.8 (19.2) 118.0 (19.8) 0.007 292.2 (17.8) 496.0 (17.8) -0.001 376.5 (17.1) 614.0 (18.1) 0.010 
2_1.2LT2 121.9 (26.9) 172.0 (28.9) 0.020 476.3 (29.1) 930.0 (33.3) 0.042 667.0 (30.3) 1102.0 (32.5) 0.022 
3_GE2 64.8 (14.3) 96.0 (16.1) 0.018 239.8 (14.6) 413.0 (14.8) 0.002 327.2 (14.9) 509.0 (15.0) 0.002 
Missing 179.2 (39.6) 209.0 (35.1) -0.044 630.7 (38.5) 954.0 (34.2) -0.043 830.0 (37.7) 1163.0 (34.3) -0.034 
Platelet count per microL (%)          
150 or higher 302.6 (66.8) 401.0 (67.4) 0.006 1046.9 (63.9) 1893.0 (67.8) 0.039 1391.4 (63.2) 2294.0 (67.7) 0.045 
< 150 150.1 (33.2) 194.0 (32.6) -0.006 590.1 (36.0) 897.0 (32.1) -0.039 807.6 (36.7) 1091.0 (32.2) -0.045 
Missing 0.0 ( 0.0) 0.0 ( 0.0) 0.000 1.9 ( 0.1) 3.0 ( 0.1) 0.000 1.6 ( 0.1) 3.0 ( 0.1) 0.000 
Total bilirubin, mg/dL (%)          
< 1 347.4 (76.7) 456.0 (76.6) -0.001 1272.7 (77.7) 2089.0 (74.8) -0.029 1653.3 (75.1) 2545.0 (75.1) 0.000 
1 - 1.2 36.7 ( 8.1) 49.0 ( 8.2) 0.001 136.0 ( 8.3) 278.0 (10.0) 0.017 203.9 ( 9.3) 327.0 ( 9.7) 0.004 
1.2 + 64.2 (14.2) 86.0 (14.5) 0.003 202.5 (12.4) 393.0 (14.1) 0.017 311.5 (14.2) 479.0 (14.1) 0.000 
Missing 4.4 ( 1.0) 4.0 ( 0.7) -0.003 27.7 ( 1.7) 33.0 ( 1.2) -0.005 32.1 ( 1.5) 37.0 ( 1.1) -0.004 
Characteristics No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No No Yes SMD Yes No 
White Blood Count per microL (%)          
4-10 228.8 (50.5) 274.0 (46.1) -0.045 835.1 (51.0) 1261.0 (45.1) -0.058 1089.7 (49.5) 1535.0 (45.3) -0.042 
<4 136.0 (30.0) 202.0 (33.9) 0.039 508.8 (31.0) 821.0 (29.4) -0.016 692.9 (31.5) 1023.0 (30.2) -0.013 
>10 87.9 (19.4) 119.0 (20.0) 0.006 295.1 (18.0) 711.0 (25.5) 0.075 418.1 (19.0) 830.0 (24.5) 0.055 
C-reactive protein measured (%) 313.0 (69.1) 415.0 (69.7) 0.006 1016.3 (62.0) 1828.0 (65.4) 0.034 1404.8 (63.8) 2243.0 (66.2) 0.024 
D-dimer measured (%) 365.9 (80.8) 486.0 (81.7) 0.009 1366.2 (83.4) 2354.0 (84.3) 0.009 1817.9 (82.6) 2840.0 (83.8) 0.012 
Vital Signs          
Highest Temperature (F) (%)          
< 99 156.4 (34.6) 198.0 (33.3) -0.013 416.6 (25.4) 816.0 (29.2) 0.038 633.9 (28.8) 1014.0 (29.9) 0.011 
99 - 100 114.2 (25.2) 140.0 (23.5) -0.017 325.2 (19.8) 644.0 (23.1) 0.032 491.0 (22.3) 784.0 (23.1) 0.008 
100 - 102 126.3 (27.9) 183.0 (30.8) 0.029 562.0 (34.3) 878.0 (31.4) -0.029 695.5 (31.6) 1061.0 (31.3) -0.003 
102 + 52.9 (11.7) 71.0 (11.9) 0.002 327.2 (20.0) 438.0 (15.7) -0.043 368.4 (16.7) 509.0 (15.0) -0.017 
Missing 2.8 ( 0.6) 3.0 ( 0.5) -0.001 7.9 ( 0.5) 17.0 ( 0.6) 0.001 11.9 ( 0.5) 20.0 ( 0.6) 0.001 
Mean Arterial Pressure, mmHg (%)          
< 60 9.8 ( 2.2) 9.0 ( 1.5) -0.006 24.9 ( 1.5) 46.0 ( 1.6) 0.001 44.0 ( 2.0) 55.0 ( 1.6) -0.004 
60 – 69 50.0 (11.1) 51.0 ( 8.6) -0.025 245.4 (15.0) 341.0 (12.2) -0.028 289.4 (13.2) 392.0 (11.6) -0.016 
70 – 89 300.5 (66.4) 401.0 (67.4) 0.010 1106.5 (67.5) 1906.0 (68.2) 0.007 1477.4 (67.1) 2307.0 (68.1) 0.010 
90 + 91.8 (20.3) 133.0 (22.4) 0.021 254.6 (15.5) 486.0 (17.4) 0.019 386.6 (17.6) 619.0 (18.3) 0.007 
Missing 0.6 ( 0.1) 1.0 ( 0.2) 0.000 7.5 ( 0.5) 14.0 ( 0.5) 0.000 3.3 ( 0.1) 15.0 ( 0.4) 0.003 
Lowest Oxygen Saturation (%)          
< 88 6.7 ( 1.5) 11.0 ( 1.8) 0.004 175.8 (10.7) 338.0 (12.1) 0.014 179.7 ( 8.2) 349.0 (10.3) 0.021 
88 - 92 170.9 (37.7) 263.0 (44.2) 0.065 950.6 (58.0) 1686.0 (60.4) 0.024 1157.8 (52.6) 1949.0 (57.5) 0.049 
93 - 95 202.5 (44.7) 238.0 (40.0) -0.047 419.4 (25.6) 580.0 (20.8) -0.048 674.2 (30.6) 818.0 (24.1) -0.065 
96 + 59.1 (13.1) 70.0 (11.8) -0.013 65.2 ( 4.0) 119.0 ( 4.3) 0.003 148.4 ( 6.7) 189.0 ( 5.6) -0.012 




Corticosteroids No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No Yes SMD No Yes SMD 
Cohort, n 2421 595  988 2793  3409 3388  
Age, (%)          
<50 273 (11.3) 59 ( 9.9) -0.014 70 ( 7.1) 261 ( 9.3) 0.023 343 (10.1) 320 ( 9.4) -0.006 
50-59 296 (12.2) 90 (15.1) 0.029 125 (12.7) 344 (12.3) -0.003 421 (12.3) 434 (12.8) 0.005 
60-69 551 (22.8) 138 (23.2) 0.004 222 (22.5) 647 (23.2) 0.007 773 (22.7) 785 (23.2) 0.005 
70-79 772 (31.9) 195 (32.8) 0.009 341 (34.5) 1048 (37.5) 0.030 1113 (32.6) 1243 (36.7) 0.040 
80+ 529 (21.9) 113 (19.0) -0.029 230 (23.3) 493 (17.7) -0.056 759 (22.3) 606 (17.9) -0.044 
Sex: Male, (%) 2287 (94.5) 562 (94.5) 0.000 931 (94.2) 2644 (94.7) 0.004 3218 (94.4) 3206 (94.6) 0.002 
Race, (%)          
White, non-Hispanic 1240 (51.2) 321 (53.9) 0.027 526 (53.2) 1589 (56.9) 0.037 1766 (51.8) 1910 (56.4) 0.046 
Black, non-Hispanic 765 (31.6) 159 (26.7) -0.049 299 (30.3) 678 (24.3) -0.060 1064 (31.2) 837 (24.7) -0.065 
Hispanic 213 ( 8.8) 61 (10.3) 0.015 78 ( 7.9) 290 (10.4) 0.025 291 ( 8.5) 351 (10.4) 0.018 
Other 123 ( 5.1) 28 ( 4.7) -0.004 55 ( 5.6) 152 ( 5.4) -0.001 178 ( 5.2) 180 ( 5.3) 0.001 
Unknown 80 ( 3.3) 26 ( 4.4) 0.011 30 ( 3.0) 84 ( 3.0) 0.000 110 ( 3.2) 110 ( 3.2) 0.000 
Phase (Admission Date) , (%)          
1: June 7 - July 11 430 (17.8) 51 ( 8.6) -0.092 289 (29.3) 270 ( 9.7) -0.196 719 (21.1) 321 ( 9.5) -0.116 
2: July 12 - Aug. 15 456 (18.8) 79 (13.3) -0.056 201 (20.3) 490 (17.5) -0.028 657 (19.3) 569 (16.8) -0.025 
3: Aug. 16 - Oct. 17 525 (21.7) 139 (23.4) 0.017 201 (20.3) 587 (21.0) 0.007 726 (21.3) 726 (21.4) 0.001 
4: Oct. 18 - Dec. 5 1010 (41.7) 326 (54.8) 0.131 297 (30.1) 1446 (51.8) 0.217 1307 (38.3) 1772 (52.3) 0.140 
Site Dexamethasone Prescribing, (%)          
Low 690 (28.5) 84 (14.1) -0.144 295 (29.9) 421 (15.1) -0.148 985 (28.9) 505 (14.9) -0.140 
Medium 1473 (60.8) 358 (60.2) -0.007 572 (57.9) 1665 (59.6) 0.017 2045 (60.0) 2023 (59.7) -0.003 
High 258 (10.7) 153 (25.7) 0.151 121 (12.2) 707 (25.3) 0.131 379 (11.1) 860 (25.4) 0.143 
Smoking Status, (%)          
Never Smoked 842 (34.8) 203 (34.1) -0.007 337 (34.1) 939 (33.6) -0.005 1179 (34.6) 1142 (33.7) -0.009 
Former Smoker 908 (37.5) 269 (45.2) 0.077 411 (41.6) 1305 (46.7) 0.051 1319 (38.7) 1574 (46.5) 0.078 
Current Smoker 626 (25.9) 112 (18.8) -0.070 211 (21.4) 506 (18.1) -0.032 837 (24.6) 618 (18.2) -0.063 
Unknown 45 ( 1.9) 11 ( 1.8) 0.000 29 ( 2.9) 43 ( 1.5) -0.014 74 ( 2.2) 54 ( 1.6) -0.006 
AUDIT-C Score (%)          
0 1489 (61.5) 369 (62.0) 0.005 645 (65.3) 1767 (63.3) -0.020 2134 (62.6) 2136 (63.0) 0.004 
1 – 3 481 (19.9) 132 (22.2) 0.023 204 (20.6) 674 (24.1) 0.035 685 (20.1) 806 (23.8) 0.037 
4 – 7 167 ( 6.9) 34 ( 5.7) -0.012 39 ( 3.9) 147 ( 5.3) 0.013 206 ( 6.0) 181 ( 5.3) -0.007 
8 + 81 ( 3.3) 15 ( 2.5) -0.008 20 ( 2.0) 43 ( 1.5) -0.005 101 ( 3.0) 58 ( 1.7) -0.013 
Unknown 203 ( 8.4) 45 ( 7.6) -0.008 80 ( 8.1) 162 ( 5.8) -0.023 283 ( 8.3) 207 ( 6.1) -0.022 
Comorbidities          
Myocardial Infarction (%) 208 ( 8.6) 36 ( 6.1) -0.025 89 ( 9.0) 216 ( 7.7) -0.013 297 ( 8.7) 252 ( 7.4) -0.013 
Congestive Heart Failure (%) 468 (19.3) 102 (17.1) -0.022 271 (27.4) 534 (19.1) -0.083 739 (21.7) 636 (18.8) -0.029 
Cerebrovascular Disease (%) 461 (19.0) 79 (13.3) -0.058 188 (19.0) 418 (15.0) -0.041 649 (19.0) 497 (14.7) -0.044 
Dementia (%) 467 (19.3) 59 ( 9.9) -0.094 172 (17.4) 252 ( 9.0) -0.084 639 (18.7) 311 ( 9.2) -0.096 
Chronic Obstructive Pulmonary Disease 
(%) 546 (22.6) 168 (28.2) 0.057 306 (31.0) 923 (33.0) 0.021 852 (25.0) 1091 (32.2) 0.072 
Rheumatoid Arthritis (%) 34 ( 1.4) 9 ( 1.5) 0.001 14 ( 1.4) 49 ( 1.8) 0.003 48 ( 1.4) 58 ( 1.7) 0.003 
Corticosteroids No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No Yes SMD No Yes SMD 
Peptic ulcer (%) 72 ( 3.0) 9 ( 1.5) -0.015 25 ( 2.5) 55 ( 2.0) -0.006 97 ( 2.8) 64 ( 1.9) -0.010 
Liver disease, mild (%) 335 (13.8) 66 (11.1) -0.027 100 (10.1) 265 ( 9.5) -0.006 435 (12.8) 331 ( 9.8) -0.030 
Diabetes, Uncomplicated (%) 1054 (43.5) 278 (46.7) 0.032 474 (48.0) 1369 (49.0) 0.010 1528 (44.8) 1647 (48.6) 0.038 
Diabetes, Complicated (%) 704 (29.1) 168 (28.2) -0.008 318 (32.2) 819 (29.3) -0.029 1022 (30.0) 987 (29.1) -0.008 
Hemi or paraplegia (%) 84 ( 3.5) 10 ( 1.7) -0.018 36 ( 3.6) 52 ( 1.9) -0.018 120 ( 3.5) 62 ( 1.8) -0.017 
Liver disease, moderate-severe (%) 56 ( 2.3) 9 ( 1.5) -0.008 13 ( 1.3) 32 ( 1.1) -0.002 69 ( 2.0) 41 ( 1.2) -0.008 
Metastatic cancer (%) 56 ( 2.3) 6 ( 1.0) -0.013 16 ( 1.6) 46 ( 1.6) 0.000 72 ( 2.1) 52 ( 1.5) -0.006 
HIV (%) 32 ( 1.3) 10 ( 1.7) 0.004 13 ( 1.3) 20 ( 0.7) -0.006 45 ( 1.3) 30 ( 0.9) -0.004 
Renal disease (%) 610 (25.2) 140 (23.5) -0.017 284 (28.7) 656 (23.5) -0.053 894 (26.2) 796 (23.5) -0.027 
Charlson Comorbidities Count (%)          
0 499 (20.6) 134 (22.5) 0.019 179 (18.1) 518 (18.5) 0.004 678 (19.9) 652 (19.2) -0.006 
1 - 2 737 (30.4) 200 (33.6) 0.032 278 (28.1) 934 (33.4) 0.053 1015 (29.8) 1134 (33.5) 0.037 
3 - 4 529 (21.9) 131 (22.0) 0.002 235 (23.8) 702 (25.1) 0.013 764 (22.4) 833 (24.6) 0.022 
5 + 656 (27.1) 130 (21.8) -0.052 296 (30.0) 639 (22.9) -0.071 952 (27.9) 769 (22.7) -0.052 
Number of Doctors (prior year) (%)          
0 1057 (43.7) 250 (42.0) -0.016 395 (40.0) 1075 (38.5) -0.015 1452 (42.6) 1325 (39.1) -0.035 
1 653 (27.0) 182 (30.6) 0.036 246 (24.9) 780 (27.9) 0.030 899 (26.4) 962 (28.4) 0.020 
2 - 4 645 (26.6) 155 (26.1) -0.006 316 (32.0) 879 (31.5) -0.005 961 (28.2) 1034 (30.5) 0.023 
5 + 66 ( 2.7) 8 ( 1.3) -0.014 31 ( 3.1) 59 ( 2.1) -0.010 97 ( 2.8) 67 ( 2.0) -0.009 
Specialty clinics attended 
Cardiology (%) 580 (24.0) 147 (24.7) 0.007 296 (30.0) 759 (27.2) -0.028 876 (25.7) 906 (26.7) 0.010 
Coagulation (%) 38 ( 1.6) 13 ( 2.2) 0.006 21 ( 2.1) 31 ( 1.1) -0.010 59 ( 1.7) 44 ( 1.3) -0.004 
Pacemaker (%) 93 ( 3.8) 20 ( 3.4) -0.005 48 ( 4.9) 70 ( 2.5) -0.024 141 ( 4.1) 90 ( 2.7) -0.015 
Dialysis (%) 32 ( 1.3) 5 ( 0.8) -0.005 32 ( 3.2) 33 ( 1.2) -0.021 64 ( 1.9) 38 ( 1.1) -0.008 
Gastoenterology (%) 203 ( 8.4) 61 (10.3) 0.019 86 ( 8.7) 292 (10.5) 0.018 289 ( 8.5) 353 (10.4) 0.019 
Hepatology (%) 97 ( 4.0) 10 ( 1.7) -0.023 30 ( 3.0) 64 ( 2.3) -0.007 127 ( 3.7) 74 ( 2.2) -0.015 
Homeless (%) 199 ( 8.2) 30 ( 5.0) -0.032 58 ( 5.9) 93 ( 3.3) -0.025 257 ( 7.5) 123 ( 3.6) -0.039 
Prophylactic Anticoagulants 1267 (52.3) 332 (55.8) 0.035 523 (52.9) 1643 (58.8) 0.059 1790 (52.5) 1975 (58.3) 0.058 
Co-medications          
Remdesivir, 1st 48 hours (%) 174 ( 7.2) 257 (43.2) 0.360 211 (21.4) 2001 (71.6) 0.503 385 (11.3) 2258 (66.6) 0.554 
Laboratory Results          
Albumin, g/dL  (%)          
3.5 + 1050 (43.4) 218 (36.6) -0.067 305 (30.9) 781 (28.0) -0.029 1355 (39.7) 999 (29.5) -0.103 
3 - 3.49 719 (29.7) 203 (34.1) 0.044 344 (34.8) 1005 (36.0) 0.012 1063 (31.2) 1208 (35.7) 0.045 
< 3 478 (19.7) 151 (25.4) 0.056 285 (28.8) 928 (33.2) 0.044 763 (22.4) 1079 (31.8) 0.095 
Missing 174 ( 7.2) 23 ( 3.9) -0.033 54 ( 5.5) 79 ( 2.8) -0.026 228 ( 6.7) 102 ( 3.0) -0.037 
Alanine aminotransferase, IU/L (%)          
< 20 784 (32.4) 148 (24.9) -0.075 290 (29.4) 578 (20.7) -0.087 1074 (31.5) 726 (21.4) -0.101 
20 - 39 938 (38.7) 242 (40.7) 0.019 418 (42.3) 1201 (43.0) 0.007 1356 (39.8) 1443 (42.6) 0.028 
40 + 533 (22.0) 199 (33.4) 0.114 227 (23.0) 977 (35.0) 0.120 760 (22.3) 1176 (34.7) 0.124 
Missing 166 ( 6.9) 6 ( 1.0) -0.058 53 ( 5.4) 37 ( 1.3) -0.040 219 ( 6.4) 43 ( 1.3) -0.052 
Asparate aminostransferase, IU/L (%)          
< 20 654 (27.0) 65 (10.9) -0.161 199 (20.1) 218 ( 7.8) -0.123 853 (25.0) 283 ( 8.4) -0.167 
20 - 39 1098 (45.4) 279 (46.9) 0.015 444 (44.9) 1218 (43.6) -0.013 1542 (45.2) 1497 (44.2) -0.010 
Corticosteroids No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No Yes SMD No Yes SMD 
40 + 669 (27.6) 251 (42.2) 0.146 345 (34.9) 1357 (48.6) 0.137 1014 (29.7) 1608 (47.5) 0.177 
Creatinine, mg/dL (%)          
< 1.2 1223 (50.5) 277 (46.6) -0.040 423 (42.8) 1324 (47.4) 0.046 1646 (48.3) 1601 (47.3) -0.010 
1.2 – 1.99 797 (32.9) 244 (41.0) 0.081 374 (37.9) 1048 (37.5) -0.003 1171 (34.4) 1292 (38.1) 0.038 
2 + 360 (14.9) 74 (12.4) -0.024 186 (18.8) 421 (15.1) -0.038 546 (16.0) 495 (14.6) -0.014 
Missing 41 ( 1.7) 0 ( 0.0) -0.017 5 ( 0.5) 0 ( 0.0) -0.005 46 ( 1.3) 0 ( 0.0) -0.013 
Fibrosis-4 Index (%)          
< 1.45 550 (22.7) 129 (21.7) -0.010 162 (16.4) 411 (14.7) -0.017 712 (20.9) 540 (15.9) -0.049 
1.45 – 3.25 994 (41.1) 239 (40.2) -0.009 394 (39.9) 1260 (45.1) 0.052 1388 (40.7) 1499 (44.2) 0.035 
3.25 + 697 (28.8) 220 (37.0) 0.082 377 (38.2) 1081 (38.7) 0.005 1074 (31.5) 1301 (38.4) 0.069 
Missing 180 ( 7.4) 7 ( 1.2) -0.063 55 ( 5.6) 41 ( 1.5) -0.041 235 ( 6.9) 48 ( 1.4) -0.055 
Lactate, mmol/L (%)          
1_1.2 361 (14.9) 118 (19.8) 0.049 172 (17.4) 496 (17.8) 0.003 533 (15.6) 614 (18.1) 0.025 
2_1.2LT2 514 (21.2) 172 (28.9) 0.077 254 (25.7) 930 (33.3) 0.076 768 (22.5) 1102 (32.5) 0.100 
3_GE2 250 (10.3) 96 (16.1) 0.058 151 (15.3) 413 (14.8) -0.005 401 (11.8) 509 (15.0) 0.033 
Missing 1296 (53.5) 209 (35.1) -0.184 411 (41.6) 954 (34.2) -0.074 1707 (50.1) 1163 (34.3) -0.157 
Platelet count per microL (%)          
150 or higher 1631 (67.4) 401 (67.4) 0.000 613 (62.0) 1893 (67.8) 0.057 2244 (65.8) 2294 (67.7) 0.019 
< 150 744 (30.7) 194 (32.6) 0.019 371 (37.6) 897 (32.1) -0.054 1115 (32.7) 1091 (32.2) -0.005 
Missing 46 ( 1.9) 0 ( 0.0) -0.019 4 ( 0.4) 3 ( 0.1) -0.003 50 ( 1.5) 3 ( 0.1) -0.014 
Total bilirubin, mg/dL (%)          
< 1 1799 (74.3) 456 (76.6) 0.023 734 (74.3) 2089 (74.8) 0.005 2533 (74.3) 2545 (75.1) 0.008 
1 - 1.2 182 ( 7.5) 49 ( 8.2) 0.007 94 ( 9.5) 278 (10.0) 0.004 276 ( 8.1) 327 ( 9.7) 0.016 
1.2 + 290 (12.0) 86 (14.5) 0.025 111 (11.2) 393 (14.1) 0.028 401 (11.8) 479 (14.1) 0.024 
Missing 150 ( 6.2) 4 ( 0.7) -0.055 49 ( 5.0) 33 ( 1.2) -0.038 199 ( 5.8) 37 ( 1.1) -0.047 
White Blood Count per microL (%)          
4-10 1494 (61.7) 274 (46.1) -0.157 564 (57.1) 1261 (45.1) -0.119 2058 (60.4) 1535 (45.3) -0.151 
<4 606 (25.0) 202 (33.9) 0.089 269 (27.2) 821 (29.4) 0.022 875 (25.7) 1023 (30.2) 0.045 
>10 321 (13.3) 119 (20.0) 0.067 155 (15.7) 711 (25.5) 0.098 476 (14.0) 830 (24.5) 0.105 
C-reactive protein measured (%) 1281 (52.9) 415 (69.7) 0.168 563 (57.0) 1828 (65.4) 0.085 1844 (54.1) 2243 (66.2) 0.121 
D-dimer measured (%) 1712 (70.7) 486 (81.7) 0.110 775 (78.4) 2354 (84.3) 0.058 2487 (73.0) 2840 (83.8) 0.109 
Viral Signs          
Highest Temperature (F) (%)          
< 99 1051 (43.4) 198 (33.3) -0.101 279 (28.2) 816 (29.2) 0.010 1330 (39.0) 1014 (29.9) -0.091 
99 - 100 606 (25.0) 140 (23.5) -0.015 230 (23.3) 644 (23.1) -0.002 836 (24.5) 784 (23.1) -0.014 
100 - 102 537 (22.2) 183 (30.8) 0.086 319 (32.3) 878 (31.4) -0.009 856 (25.1) 1061 (31.3) 0.062 
102 + 220 ( 9.1) 71 (11.9) 0.028 158 (16.0) 438 (15.7) -0.003 378 (11.1) 509 (15.0) 0.039 
Missing 7 ( 0.3) 3 ( 0.5) 0.002 2 ( 0.2) 17 ( 0.6) 0.004 9 ( 0.3) 20 ( 0.6) 0.003 
Mean Arterial Pressure, mmHg (%)          
< 60 63 ( 2.6) 9 ( 1.5) -0.011 37 ( 3.7) 46 ( 1.6) -0.021 100 ( 2.9) 55 ( 1.6) -0.013 
60 – 69 322 (13.3) 51 ( 8.6) -0.047 148 (15.0) 341 (12.2) -0.028 470 (13.8) 392 (11.6) -0.022 
70 – 89 1575 (65.1) 401 (67.4) 0.023 643 (65.1) 1906 (68.2) 0.032 2218 (65.1) 2307 (68.1) 0.030 
90 + 455 (18.8) 133 (22.4) 0.036 159 (16.1) 486 (17.4) 0.013 614 (18.0) 619 (18.3) 0.003 
Corticosteroids No Oxygen Nasal Canula Combined Cohort 
No Yes SMD No Yes SMD No Yes SMD 
Missing 6 ( 0.2) 1 ( 0.2) -0.001 1 ( 0.1) 14 ( 0.5) 0.004 7 ( 0.2) 15 ( 0.4) 0.002 
Lowest Oxygen Saturation (%)          
< 88 30 ( 1.2) 11 ( 1.8) 0.006 78 ( 7.9) 338 (12.1) 0.042 108 ( 3.2) 349 (10.3) 0.071 
88 - 92 630 (26.0) 263 (44.2) 0.182 489 (49.5) 1686 (60.4) 0.109 1119 (32.8) 1949 (57.5) 0.247 
93 - 95 1198 (49.5) 238 (40.0) -0.095 311 (31.5) 580 (20.8) -0.107 1509 (44.3) 818 (24.1) -0.201 
96 + 508 (21.0) 70 (11.8) -0.092 92 ( 9.3) 119 ( 4.3) -0.051 600 (17.6) 189 ( 5.6) -0.120 
Missing 55 ( 2.3) 13 ( 2.2) -0.001 18 ( 1.8) 70 ( 2.5) 0.007 73 ( 2.1) 83 ( 2.4) 0.003 
  
Supplemental Table 2. Sensitivity analyses estimating the average treatment effect in the treated population (ATT) in weighted Cox 
proportional hazards models for the association of corticosteroids with all-cause 90-day mortality among those not on IRS 
 
No oxygen 
supplementation Nasal cannula 
Combined group: no oxygen 
plus NC 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Primary analysis 1.77 (1.25-2.50) 1.26 (0.92-1.74) 1.60 (1.24-2.08) 
Subgroup analyses    
Restricted to dexamethasone  1.55 (0.95-2.52) 1.28 (0.84-1.94) 1.49 (1.02-2.18) 
Excluding patients admitted to ICU in initial 48 
hours 
1.62 (1.05-2.49) 1.33 (0.88-1.99) 1.60 (1.15-2.24) 
Restricted to patients age 70 and older 1.69 (1.13-2.54) 1.49 (0.99-2.24) 1.72 (1.24-2.40) 
Models present the ATT (average treatment effect in treated population).   
CI = confidence interval 
HR = hazard ratio 




Supplemental Table 3. Sensitivity analyses with unweighted, multivariable Cox proportional hazards regression models for the association of 
corticosteroids with all-cause 90-day mortality  
 
No oxygen 
supplementation Nasal cannula 
Combined group: no oxygen 
plus NC 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Primary analysis 1.87 (1.36-2.57) 1.39 (1.10-1.76) 1.66 (1.39-1.99) 
Subgroup analyses    
Restricted to dexamethasone  1.87 (1.32-2.66) 1.37 (1.08-1.74) 1.66 (1.38-1.99) 
Excluding patients admitted to ICU in initial 48 
hours 
1.85 (1.31-2.62) 1.31 (1.01-1.69) 1.63 (1.34-1.98) 
Restricted to patients age 70 and older 2.02 (1.40-2.89) 1.41 (1.09-1.82) 1.66 (1.36-2.02) 
CI = confidence interval 
HR = hazard ratio 
IRS = intensive respiratory support 
 
  
Supplemental Table 4. STROBE Checklist of items for cohort studies  
 Item No Recommendation Section/Paragraph 
 Title and abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract 
Abstract: Methods 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 





Background/rationale 2 Explain the scientific background and rationale 
for the investigation being reported 
Introduction: 
Paragraphs 1-2 









Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection 
Methods: Paragraph 
1 
Participants 6 (a) Give the eligibility criteria, and the sources 
and methods of selection of participants. 
Describe methods of follow-up 
Methods: Paragraphs 
1-2 
(b) For matched studies, give matching criteria 
and number of exposed and unexposed 
N/A  
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 




Data sources/ measurement 8*  For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement). Describe comparability of 




Bias 9 Describe any efforts to address potential 
sources of bias 
Methods: Paragraphs 
7-8 
Study size 10 Explain how the study size was arrived at All hospitalized 
COVID+ patients with 
at least 48h stay, 
concatenating length 




Quantitative variables 11 Explain how quantitative variables were 
handled in the analyses. If applicable, describe 
which groupings were chosen and why 
Methods: paragraphs 
4, 6, Table 2, 
Supplemental Table 1 
Statistical methods 12 (a) Describe all statistical methods, including 
those used to control for confounding 
Methods: paragraphs 
7, 8 
(b) Describe any methods used to examine 
subgroups and interactions 
Methods: paragraph 
9 
(c) Explain how missing data were addressed Methods: paragraph 
8, Table 2, 
Supplemental Table 1 
(d) If applicable, explain how loss to follow-up 
was addressed 
N/A 
(e) Describe any sensitivity analyses Methods: paragraph 
9 
Results  
Participants 13* (a) Report numbers of individuals at each 
stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed 
eligible, included in the study, completing 
follow-up, and analysed 
Methods: paragraph 
1-2 
Results: paragraph 1 
Figure 1 





(c) Consider use of a flow diagram Figure 1 
Descriptive data 14* (a) Give characteristics of study participants 
(eg demographic, clinical, social) and 





(b) Indicate number of participants with 
missing data for each variable of interest 
Table 2, 
Supplemental Table 1 
(c) Summarise follow-up time (eg, average and 
total amount) 
Figure 2 
Outcome data 15* Report numbers of outcome events or 
summary measures over time 
Results: paragraph 2 
Table 1, Figure 2, 
Figure 3 
Main results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (eg, 95% confidence 
interval). Make clear which confounders were 
adjusted for and why they were included 






(b) Report category boundaries when 
continuous variables were categorized 
Table 2 and 
Supplemental Table 1 
(c) If relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of 
subgroups and interactions, and sensitivity 
analyses 
Results: paragraph 6 
Discussion  




Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias 
Discussion: 
paragraph 7 
Interpretation 20 Give a cautious overall interpretation of 
results considering objectives, limitations, 
multiplicity of analyses, results from similar 
studies, and other relevant evidence 
Discussion: 
paragraphs 1, 2, 3, 5, 
6 
Generalisability 21 Discuss the generalisability (external validity) 
of the study results 
Discussion: 
paragraph 3, 4, 5, 6 
Other information  
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if 
applicable, for the original study on which the 
present article is based 
Metadata 
 
*Give information separately for exposed and unexposed groups. 
 
 
 
 
 
 
 
